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Abstract 
 
Epilepsy is a disorder which affects approximately 1% of the world’s 
population. It is possible to explain the underlying mechanisms of epilepsy by not only 
alterations in genetic structure and environmental factors, but also epigenetic 
mechanisms. As a significant epigenetic modification, DNA methylation may play a 
crucial role for understanding biological pathways related to epilepsy.  
Even though the relationship between CpG islands, DNA methylation and gene 
expression is quite complex, in this thesis we aimed to determine significant biological 
pathways related to epilepsy, using the difference of methylation levels at CpG loci in 
family trios. Dataset was gathered from 10 family trios (30 individuals) and it includes 
methylation level information for each CpG locus determined by Illumina 
HumanMethylation450 Bead Chip which is a microarray based analysis tool. 
Considering the difference of methylation levels at each CpG locus, we prepared lists of 
genes that we marked as significant. Applying several filters to the dataset allowed us to 
gather more reliable information from the dataset. We identified a number of significant 
pathways that may be related to epilepsy, especially immune system related pathways 
stand out as a significant and novel finding. 
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Özet 
 
Epilepsi, dünya nüfusunun yaklaşık %1'ini etkileyen bir hastalıktır. Epilepsinin 
ardında bulunan sebepleri sadece genetik yapıda değişiklikler ve çevresel faktörler ile 
değil, aynı zamanda epigenetik mekanizmalarla açıklamak mümkündür. Önemli bir 
epigenetik değişikliği olan DNA metilasyonu, epilepsi ile ilgili biyolojik yolakları 
anlamak için önemli bir role sahip olma ihtimalini barındırmaktadır. 
CpG adaları, DNA metilasyonu ve gen ifadesi arasındaki ilişki oldukça karmaşık 
olsa da, üç kişilik ailelere ait CpG bölgelerinin metilasyon seviyelerinin farkı 
incelenerek epilepsi ile ilgili önemli biyolojik yolakların belirlenmesi bu tezin 
hedeflerinden birisi olmuştur. Illumina HumanMethylation450 Bead Chip adlı 
mikrodizi tabanlı analiz aracı yardımıyla 10 farklı 3 kişilik aileden (30 kişi) toplanan, 
CpG bölgelerinin içindeki metilasyon düzeyleri içeriğine sahip veri kümesi analiz 
edilmiştir. Her CpG bölgesine ait metilasyon seviyelerindeki fark göz önüne alınarak, 
önemli görülen genlerin listesi oluşturulmuştur. Veri kümesine çeşitli filtreler 
uygulanarak daha güvenilir sonuçlar elde edilmiştir. Epilepsi ile ilgili olabilecek bir 
takım önemli yolaklar tespit edilmiş, bunların içinde özellikle bağışıklık sistemi ile ilgili 
olanların tespit edilmesi önemli ve yeni bir bulgu olarak dikkat çekmiştir. 
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CHAPTER 1 
Introduction 
Epilepsy is a common neurological condition which affects approximately 1% of 
the world’s population. It is defined by recurrent, unprovoked seizures that can cause 
motor, sensory, cognitive, psychic or autonomic disturbances. By convention, its 
diagnosis requires the patient whom has had at least two unprovoked seizures. Seizures 
may last between a few seconds and a few minutes (Steinlein, 2004). In most cases, 
epilepsy is controlled with medication, but not cured.  
 
Instead of being considered as a single disorder, epilepsy can be differentiated 
into several clinical subtypes. Clinical classification of epilepsy defines the general 
categories as symptomatic, presumed symptomatic and idiopathic epilepsy. The cases 
where the patient develops recurrent unprovoked seizures for no obvious reason and 
without any other neurological abnormalities are called as idiopathic epilepsies, and 
they are mainly caused by genetic reasons. Most idiopathic epilepsies occur with a 
greater frequency in relatives of affected individuals (Kaneko & Wada, 1998), but they 
do not exhibit a single Mendelian inheritance pattern (Kaneko et al., 2002). Multiple 
genes are simultaneously involved in the process of epileptogenesis, which describes 
the process that leads to development of recurrent unprovoked seizures in a previously 
healthy brain.  
 
Although all modes of inheritance are found in epilepsies, including autosomal, 
X-chromosomal, mitochondrial and complex inheritance (Steinlein, 2004), epigenetic 
modifications associated with transgenerational inheritance also play role in a number 
of circumstances related with epilepsy. Epigenetic modifications describe heritable 
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changes in gene function without any alterations in the nucleotide sequence. DNA 
methylation is considered as a significant epigenetic modification and it can be 
associated with epileptogenesis under some circumstances.  
 
CpG islands (CpG rich regions in DNA) are usually hypomethylated, and they 
are associated with approximately 60% of human genes (Antequera & Bird, 1993), over 
50% of them in their promoter regions (Larsen et al., 1992; Wang et al., 2004). DNA 
methylation in these regions may have effects in gene expression. Even though the role 
of DNA methylation in promoters and/or CpG islands has long been appreciated, the 
relationship between CpG islands, methylation and gene expression is quite complex, 
therefore making it an important and intriguing research area. 
 
The aim of this study is to identify functionally important biological pathways 
related to epilepsy. Main focus of the thesis is to study the effects of the difference in 
methylation levels in upstream regions of the genes between disease and control groups. 
Methylation status of each CpG locus were determined and used to mark related genes 
and these related genes were used to determine significant pathways. In order to find 
common motifs in methylated and unmethylated CpG island sequences, a computational 
method that determines CpG island nucleotide composition is also applied.  
 
Background information on related concepts can be found in Chapter 2, whereas 
details of the dataset and applied methods are presented in Chapter 3. Results are shown 
in Chapter 4 and discussion of the results and future projections can be found in Chapter 
5. Several Appendices provide details about certain parts of analysis results.  
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CHAPTER 2 
Background Information 
DNA (Deoxyribonucleic Acid) is a molecule that contains heredity information 
in humans and almost all other organisms. Two polynucleotide chains, in other words 
strands, run in opposite directions around the common axis, hence having the name 
double helix structure. Each strand consists of smaller units called nucleotides, which 
are composed of nucleobases and a backbone made of sugars and phosphate groups.  
Those bases are Adenine (A), Guanine (G), Cytosine (C) and Thymine (T), and they are 
bonded to deoxyribose sugar with covalent bonds.  
 
Sequences of nucleotides encode genetic information by specifying the sequence 
of amino acids within proteins. Segments of DNA that code for polypeptides and 
functional Ribonucleic Acid (RNA) chains are called genes. The information carried by 
genes is read in transcription process which transfers the sequence information to RNA 
to be used in protein synthesis. 
 
There are some particular regions in DNA sequence which initiate transcription 
of genes. These regions are called promoters and they are located near genes. Promoters 
play a crucial role in gene expression since they are regulatory regions which control 
the transcription process of a gene.  
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2.1. Methylation 
DNA Methylation is a significant epigenetic modification which plays a vital 
role in transcriptional regulation, chromatin remodeling (Wang et al., 2012), 
chromosomal stability, genomic imprinting and X-inactivation (Rakyan et al., 2008). 
Also the aberration of DNA methylation profile is associated with many human diseases 
including cancer (Wang et al., 2012). 
 
DNA Methylation was first found to influence gene expression in 1975.  It was 
accepted that both adenine and cytosine residues were capable of being methylated in 
bacteria, however only methylated cytosines were possessed by higher organisms 
(Harrison & Parle-McDermott, 2011). In eukaryotic genomes, DNA methylation 
appears as a cytosine methylated at the 5-carbon position (Antequera, 2007). In 
mammals, DNA methylation is primarily restricted to CpG dinucleotides (Smith and 
Meissner, 2013). Because of that, DNA methylation is often referred according to 
methylation or non-methylation of CpG dinucleotides. Since a methylated CpG is 
matched by another methylated CpG in the complementary strand, methylation on the 
DNA double helix is symmetrically organized (Antequera, 2007). Mammalian genomes 
are globally CpG-depleted, and approximately 60-80% of CpG in the human genome 
are methylated (Smith & Meissner, 2013). Huge number of possible methylation 
patterns may exist and the information that carried out by these patterns can be changed 
without any alteration to the nucleotide sequence. Moreover, during DNA replication 
part of the cell division, CpGs in the daughter strand are methylated only when they are 
complementary to methylated CpGs in the parental strand.  This regulation provides a 
protection mechanism for the inheritance of DNA methylation (Antequera, 2007).  
2.2. CpG Islands 
 One of the most significant features of DNA methylation appears in CpG rich 
regions, so called CpG islands, which are usually hypomethylated. Approximately 60% 
of human genes are associated with CpG islands (Antequera & Bird, 1993) and over 
50% of human genes are associated with CpG islands in their promoter regions (Larsen 
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et al., 1992; Wang et al., 2004). However CpG islands can stay methylation-free when 
their associated gene is silent, because many CpG islands are located at genes that have 
a tissue-restricted expression pattern. On the other hand, a small but significant fraction 
of CpG islands become methylated during development, and their associated promoters 
remain silent. A significant amount of all human CpG islands are prone to progressive 
methylation in certain tissues during aging or in abnormal cells such as cancers and 
permanent cell lines (Bird, 2002).  
 
Originally, CpG islands were identified by an epigenetic property, which is the 
absence of DNA methylation (Bock et al., 2007). When the genomic DNA was 
experimentally digested with restriction enzyme isoschizomers that differed only by 
their sensitivity to cytosine methylation (Singer et al., 1979), the genome were digested 
to completion by the methylation-insensitive MspI (5′-CCGG-3′) enzyme, whereas most 
of the DNA exposed to its methylation-sensitive isoschizomer HpaII remains high-
molecular weight (Fazzari & Greally, 2004). It is concluded that a small but significant 
fraction of the genome is reproducibly unmethylated, and the hypomethylated part of 
the genome digested by HpaII were called HpaII tiny fragments (HTFs) (Bird et al., 
1986).  When HTFs were cloned and sequenced, it is discovered that they were highly 
(G+C) and CpG rich (Bird et al., 1986).  
 
According to another research based on this information, CpG Island definition 
was made and its criteria known as Gardiner-Garden sequence criteria were set (Bock et 
al., 2007). According to this criteria, a genomic region must fulfill the following criteria 
to be classified as a CpG Island:  (1) (G+C) content should be above 50%, (2) observed 
to expected CpG dinucleotide ratio should be 0.60 or greater, (3) the length of the 
sequence should be greater than 200 basepairs (bp) (Gardiner-Garden & Frommer, 
1987).  
 
The identification of CpG islands, still remains as a great model for today’s 
epigenomic studies (Fazzari & Greally, 2004). After the discovery, CpG islands have 
been subject to extensive research (Bock et al., 2007). Today it is known that CpG 
islands are present in the promoter and exonic regions of approximately 50% of 
mammalian genes. On the other hand, other regions of the mammalian genome contain 
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few CpG dinucleotides and these are largely methylated (Larsen et al., 1992). Since 
methylated cytosines are mutational hotspots (Coulondre et al., 1978) which lead to 
CpG depletion during evolution, the decrease in the occurrence of CpGs can be 
explained by this fact (Takai & Jones, 2002). CpG islands are associated with more than 
75% of all known transcriptional start sites (Bajic et al., 2006) and 88% of active 
promoters identified in primary fibroblasts (Kim et al., 2005). Moreover, CpG islands 
are hotspots of specific histone modifications (Bernstein et al., 2005), they frequently 
bind ubiquitous transcription factors such as SP1 (Cawley et al., 2004), and they exhibit 
particularly accessible chromatin structures (Crawford et al., 2006). For these reasons 
CpG Islands have become a significant element for genome analysis and annotation 
(Bock et al., 2007).  
2.3. Epigenetics 
There exist a few different definitions for the term ―epigenetics‖, because the 
word itself has several different meanings with independent roots (Bird, 2007). One 
definition describes epigenetics as the study of epigenesis, which means how genotypes 
give rise to phenotypes during development (Waddington, 1957). Another definition 
explains the word as ―the study of mitotically and/or meiotically heritable changes in 
gene function that cannot be explained by changes in DNA sequence‖ (Riggs et al., 
1996). Bird suggested a unifying definition for epigenetic events as the following: ―the 
structural adaptation of chromosomal regions so as to register, signal or perpetuate 
altered activity states‖ (Bird, 2007).   
 
DNA methylation and the Polycomb/Trithorax systems are considered classic 
epigenetic systems, because the alterations in these systems are inherited by subsequent 
generations of cells and sometimes organisms. Epimutations cause the epigenetic 
inheritance, without altering the nucleotide sequence. Transmission of DNA 
methylation at a locus from generation to generation is a significant type of 
epimutations. Even though examples of transgenereational epigenetics are well 
documented in plants, epigenetic inheritance in animals have been only detected by 
highly sensitive genetic assays (Bird, 2007). 
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2.4. Epilepsy 
Epilepsy affects approximately 1% of the world’s population, including one in 
200 children (Cowan, 2002). Epilepsies are characterized by recurrent seizures which 
can cause motor, sensory, cognitive, psychic or autonomic disturbances. Even though its 
basic manifestations appear at the single neuron level, seizures are only possible 
because the brain is organized in a series of interconnected neuronal networks 
(Steinlein, 2004).  
 
Epilepsy is not considered as a single disorder, but it can be differentiated into 
several clinical subtypes. According to clinical classification of epilepsy, the general 
categories are symptomatic, presumed symptomatic and idiopathic epilepsy. Over time, 
idiopathic epilepsy definition has become the epilepsy caused by an underlying genetic 
basis, and the majority of cases in this category are likely to be influenced by genetic 
susceptibility (Poduri, 2011). 
 
Epileptogenesis is the definition of the process that leads to development of 
recurrent unprovoked seizures in a previously healthy brain. ―Epileptogenesis is 
associated with complex temporal and spatial abnormalities of neural network structure 
and activity mediated by posttranslational modifications of proteins, activation of 
immediate early genes (IEGs), and other alterations in profiles of gene expression and 
function (e.g., GABAA receptor subunit, CREB, JAK-STAT, BDNF, and EGR3) that 
eventually lead to deregulated neural circuits with a predisposition for synchronous 
electrical activity‖ (Rakhade & Jensen, 2009). 
 
Epilepsy is explained by not only alterations in genetic structure and 
environmental factors, but also epigenetic mechanisms. Recent studies show that, 
interconnected epigenetic regulatory networks play significant roles in modulation of 
cellular and organismal development, homeostasis and aging. Epigenetic mechanisms 
are also associated with transgenerational inheritance and ―they are critical for 
promoting brain patterning, neural stem cell (NSC) maintenance and proliferation, 
neurogenesis and gliogenesis, cellular migration, and synaptic and neural network 
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connectivity and plasticity and are also implicated in orchestrating sophisticated 
cognitive functions including learning and memory‖ (Mehler, 2008).  
 
Recent studies provide evidence for the fact that, DNA methylation, as a crucial 
epigenetic mechanism, results in a number of circumstances that are associated with 
epilepsy. DNA methyltransferase, an enzyme which catalyzes DNA methylation and 
methyl-CpG-binding domain proteins are regulated throughout a few number of 
processes (e.g., cell fate specification, maturation and survival and during activity-
dependent synaptic plasticity) that can be associated with pathopsyiology of epilepsy 
(Sharma et al., 2008). Another study shows that epileptic syndromes that are associated 
with MeCP2 gene disruption are resulted by epigenetic dysregulations (Qureshi, 2010). 
High levels of DNA methylation in the promoter region of the critical neural factor, 
Reelin (RELN), are associated with the pathogenesis of temporal lobe epilepsy (Kobow 
et al., 2009). 
2.5. Computational Methods 
2.5.1. Prediction of Methylation Patterns 
The relationship between genomic methylation patterns and underlying DNA 
sequence remains unclear. In order to provide an explanation for this relationship, 
different computational methods have been used to predict methylation patterns using 
DNA sequence information.  
 
Mostly pattern recognition methods which rely on classifiers and clustering 
algorithms were used to predict methylation patterns. A classifier based on a Support 
Vector Machine (SVM) called MethCGI was developed. Classification features were 
nucleotide sequence contents as well as transcription factor binding sites (TFBSs) in 
this approach.  The classifier achieved specificity of 84.65% and sensitivity of 84.32% 
on the brain data, additionally it two-third of the data from other tissues reported in 
MethDB database were correctly predicted by MethCGI (Fang et al., 2006).  
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Another method called Methylator also identifies support vector machine based 
classifier as better performing in comparison to classifiers built using alternative 
machine learning and statistical algorithms including artificial neural networks, 
Bayesian statistics, and decision trees (Bhasin et al., 2005). Datasets were generated by 
fragmenting the MethDB sequence patterns into overlapping fragments of fixed length 
(window size) and fragments with a methylated cytosine in the center were considered 
as positives, whereas fragments with non-methylated cytosine in the center were 
considered as negatives. 
 
Support vector machine approach was reported as best performing classifier, in 
comparison to K means clustering, linear discriminant analysis and logistic regression, 
also in a study that presents another classifier called HDFINDER. It was reported that 
the classifier has a prediction accuracy of 86% on all 22 autosomal chromosomes (Das 
et al., 2006). For CpG islands they used 92 features including G+C content, di- and 
trinucleotide count, Alu coverage, and 10 hexamers and they applied recursive feature 
elimination which is a backward selection method and Principal Components Analysis 
(PCA) for feature subset reduction. 
 
Another study on epigenetic alterations in human non-Hodgkin’s lymphomas 
(NHL), attempted to discover methylation-expression relationships. A set of algorithms 
based on fuzzy sets theory, in particular Possibilistic c-Means (PCM) and cluster fuzzy 
density were used in the study. For each gene, these algorithms calculate measures of 
confidence of various methylation-expression relationships in each NHL subclass. The 
aim of the study was to provide a better understanding of the pathobiology of NHL and 
other types of cancer (Sjahputera et al., 2007).  
 
In another analysis with a linear support vector machine predictor, three groups 
of DNA attributes, namely certain sequence patterns, specific DNA repeats, and 
predicted DNA structure, were found to be correlated with CpG island methylation with 
correlation coefficients of 0.64, 0.66, and 0.49, respectively (Bock et al., 2006). 
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2.5.2. Analysis of Methylation Data 
Several modules were developed to be used in the analysis of Illumina Infinium 
methylation microarray data. These modules are mostly extensions of R package, which 
is a programming language package that is widely used in data mining for statistics and 
data analysis. Notable examples are IMA, which provides a pipeline that automates the 
tasks (Wang et al., 2012),  lumi, which makes use of M-value instead of β value (Du et 
al., 2008) and HumMeth27QCReport which originally targets Illumina 
HumanMethylation27, but also is compatible with HumanMethylation450 Bead Chip 
(Mancuso et al., 2011).  
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CHAPTER 3 
Materials and Methods 
3.1. CpG Island Nucleotide Composition Determination 
Analysis of CpG islands based on nucleotide sequences is a significant method 
for methylation analysis. It is frequently used for prediction of methylated CpG islands 
and determination of CpG islands that are prone to change in methylation levels.  
 
In this study, methylated and unmethylated CpG island sequences were 
compared to determine if there exist any differences between them. In order to achieve 
this goal, methylated and unmethylated CpG island sequences are analyzed in different 
window sizes. Common motifs around methylated and unmethylated CpG islands are 
devised using the frequencies of motifs.  
 
The data for this analysis is taken from MethDB database. Common motifs are 
found from the sequences using four different window sizes that are 14, 18, 22, and 30. 
The motifs are found in the form of dinucleotides and trinucleotides. 
3.2. Microarray based Methylation Analysis 
The foundations for high throughput analysis of single nucleotide 
polymorphisms and other genomic variants, was laid by the development of DNA 
microarray technology (Southern et al., 1999).  DNA microarrays allow the whole 
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genome to be monitored on a single chip, so that the gene expression levels and the 
interaction between genes can be observed simultaneously (Roland, 2005; Brazma et 
al., 2000). 
 
Three traditional methods of DNA methylation analysis, Immunoprecipitation, 
endonuclease digestion and sodium-bisulfite treatment, were all received a 
transformation with the development of DNA microarray technology. However the 
underlying principle regarding the microarray assays is same: Methylated and 
unmethylated fragments of the genome are separated and analyzed (Harrison & Parle-
McDermott, 2011).  
 
In this study, Infinium HumanMethylation450 BeadChip Kit by Illumina was 
used for methylation analysis. This platform is considered as a robust and reliable 
approach for DNA methylation analysis (Sandoval et al., 2011). This BeadChip is 
powered by the Infinium Methylation Assay which detects cytosine methylation at CpG 
islands based on highly multiplexed genotyping of bisulfite-converted genomic DNA 
(gDNA). Cytosine methylation can be detected because of the fact that, upon treatment 
with bisulfite, unmethylated cytosine bases are converted to uracil, while methylated 
cytosine bases remain unchanged (Illumina, 2012b).  
 
Making use of two Methylation Assay chemistries (Illumina, 2012a), the 
BeadChip allows the interrogation of 485,000 methylation sites per sample at single-
nucleotide resolution, thus it provides coverage of 99% of RefSeq genes, 96% of CpG 
islands, with multiple sites within islands and island shores. HumanMethylation450 
BeadChip workflow does not require PCR, the kit includes all required reagents for 
methylation analysis, except for the bisulfite conversion kit, which is available 
separately (Illumina, 2012b).   
3.3. GenomeStudio Software 
GenomeStudio Data Analysis Software is used to visualize and analyze data 
generated by all platforms of Illumina. The GenomeStudio Software has seven 
application modules which can be added to the software. Application modules include; 
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DNA sequencing module, RNA sequencing module, ChIP sequencing module, 
Genotyping module, Gene expression module, Methylation module, Protein analysis 
module.  
 
The software and its packages allow researchers to obtain a comprehensive view 
of the genome, gene expression and regulation. The data on the GenomeStudio software 
can be exported to a number of third-party software tools for further analysis. The 
GenomeStudio also allows the export of data to .csv format, which allows specific 
analysis of the data (Illumina, 2011).  
 
Illumina HumanMethylation450 Bead Chip provides signal intensities of each 
CpG location from methylation assays. This information is provided in raw data format 
and β values calculated from raw signal intensities are provided in GenomeStudio 
project. Sample GenomeStudio data is shown in Table 3.1. 
 
 
TargetID 
Sample 1 
AVG_Beta 
Sample 1 
Intensity 
Sample 2 
AVG_Beta 
Sample 2 
Intensity 
cg00000029 0.4812995 1824.655 0.5044388 2351.673 
cg00000108 0.9432696 5668.381 0.9389272 5423.673 
cg00000109 0.8908905 2541.251 0.8681602 2197.432 
cg00000165 0.1235855 1938.497 0.1880388 2583.251 
cg00000236 0.7291482 2838.623 0.6898252 2644.511 
Table 3.1 Sample GenomeStudio file with β values 
3.3.1. CpG Loci Identification 
Since CpG loci was lacking a formal method of nomenclature, unlike other 
genomic loci, Illumina developed a method to consistently designate CpG loci based on 
the actual or contextual sequence of each individual CpG locus.  
 
Illumina’s CpG loci database provides unique identification for each CpG locus 
and it can be accessed by HumanMethylation450 manifest file (Illumina, 2010). 
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3.4. Data 
The case-parent trio design is a method that widely used to detect genetic 
associations (Yu, 2011). In this design, child and one parent are affected and other 
parent is healthy, therefore healthy parent is considered as control parent. Use of case-
parent trio design may play a crucial role to address population structure bias (Infante-
Rivard et al., 2009). This design may play a crucial role in the researches regarding the 
analysis of transgenerational epigenetics, when it is used in a study on DNA 
methylation, which is an epigenetic system instead of a study on genetic inheritance. 
 
The data used in this thesis were provided in the scope of IntenC project by 
Istanbul University Capa Faculty of Medicine. The data is gathered from 30 individuals 
from 10 family trios, which consists of an offspring who has the disorder, one parent 
who has the disorder and the other parent as control. Clinic information regarding the 
disorder, phenotypes and age information are provided for each individual.  
 
DNA methylation analysis results from HumanMethylation450 BeadChip are 
provided. These results include β values and Intensity scores for each CpG locus. 
Methylation level on a CpG locus is expressed by β value. This data can be visualized in 
Illumina’s GenomeStudio. Using export option in the software, data was converted to a 
comma-separated file (a file in .csv format). While rows represent each CpG locus in 
this file, columns indicate different individuals.  
3.5. Implementation 
3.5.1. Determination of Methylation Status 
Average β values indicate the methylation level in a locus. In order to determine 
whether a loci is methylated or not, it was necessary to decide on particular range values 
for methylated status and non-methylated status. Since β value has a direct 
correspondence with methylation and its value can be interpreted as the percentage of 
methylation at a given loci, the necessary ranges were determined as the following: β 
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value between 0.0 and 0.2 indicates non-methylation and β value between 0.8 and 1.0 
indicates methylation (Du et al., 2010).  
3.5.2. Three Types of Analysis 
For the analysis, each family trio considered separately. We decided on two 
different approaches which takes account methylation status information of each 
individual of a family trio. For each approach we created a CpG list according to the 
criteria in Error! Reference source not found.. 
 
 First approach Second approach 
Offspring Methylated Non-methylated 
Parent with disorder Methylated Non-methylated 
Control parent Non-methylated Methylated 
Table 3.2 Methylation statuses of a CpG locus for each individual in a family trio 
3.5.2.1. First approach  
CpG loci should be methylated in the offspring and the parent with disorder, and 
it should be non-methylated in the control parent.  
3.5.2.2. Second approach  
CpG loci should be non-methylated in the offspring and the parent with disorder, 
and it should be methylated in the control parent.  
3.5.2.3. Third approach  
This approach is combination of first and second approaches: if there is a 
difference in the methylation status between control parent and other two samples with 
disorder (child and parent with disorder) in a CpG locus, that CpG locus is marked. 
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For all three approaches, we marked each CpG loci that fits the criteria, and 
formed two lists that consist of CpG loci identification codes according to Illumina CpG 
loci database. Manifest file of HumanMethylation450 BeadChip also indicates the genes 
that are associated with each CpG loci. This information allowed us to generate a list of 
associated genes for each approach.  
3.5.3. Filtering 
After two lists (one with CpG identification codes, another with the list of 
associated genes) were generated according to both approaches that described in the 
previous section, we proceeded to filtering the dataset.  
3.5.3.1. First filter 
Probes with no β value, all rs and ch probes and all sex chromosome probes 
were removed from the dataset.  Probes which are marked as rs indicates probes that 
measure SNPs, not probes containing SNPs and ch probes target non-CpG methylation.  
 
Among the autosomal probes, some of them display significant methylation 
differences between males and females. According to the list which was generated by 
another study (Price et al., 2013) autosomal probes with sex-differences were also 
removed from the dataset.   
 
After filtering the dataset based on previously described filtering criteria, we 
repeated the process that allows us to generate lists that include CpG identification 
codes and list of associated genes. 
3.5.3.2. Second filter 
In addition to the filtering previously described, we also decided to apply an 
extra filtering, and repeat the generation of lists. This filtering includes the removal of 
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cross-reactive probes and polymorphic CpGs. While polymorphic CpGs indicate the 
CpGs that overlap known SNPs, cross-reactive probes target repetitive sequences or 
they co-hybridize to alternate sequences that are highly homologous to the intended 
targets. Because of that, cross-reactive probes could generate spurious signals and they 
potentially lead to invalid conclusions (Chen et al., 2013). Dataset was filtered using the 
lists of cross-reactive probes and polymorphic CpGs that generated in a related study 
(Chen et al., 2013). After the extra filtering the lists of CpG identification codes and 
associated genes were generated again by repeating the process for both approaches.  
3.5.3.3. Third filter 
A third filter was developed with the aim of removal of age bias in dataset. It 
was necessary to find CpG loci in which the methylation level changes between 
individuals in correlation with their age. Since the CpG dataset is too large, Principal 
Components Analysis (PCA) was used to transform the data into principal components.  
 
PCA was implemented in MatLab using the following function: 
 [                  ]          (        )                            (3.1) 
 
In this function x denotes our methylation level data, where rows denote each 
individual as observations and columns denote each CpG loci as variables. In the 
results, coeff denotes a matrix where the number of initial variables is the number of 
rows, and the number of principal components is the number of columns. It shows the 
coefficient of each variable in each principal component. Score denotes a matrix where 
number of observations is rows and number of principal components is columns. It 
shows the transformed version of the initial data. Latent explains the variance covered 
by each principal component. Total variance can be explained by the total number of 
variables.  
 
In our analysis, 29 principal components were found. For each principal 
component, its correlation with age is determined by Pearson’s linear correlation 
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coefficient. Therefore each of these principal component scores was analyzed against 
age data.  
 
Only the 8th principal component shows low correlation with age with a 
significant p-value. Correlation is low and its latent value indicates that this principal 
component covers very low variance of the data; therefore it is safe to conclude that our 
data is not correlated with age. 
3.5.4. Statistical Analysis 
3.5.4.1. Wilcoxon rank-sum test 
Wilcoxon Rank-Sum Test is a non-parametric test for two populations which 
tests null hypothesis that two populations are from continuous distributions with equal 
medians, against the alternative that they are not. Samples should be independent for the 
test.  Wilcoxon Rank-Sum Test is equivalent to Mann-Whitney U Test.  
 
The test was implemented in MatLab using ranksum(x,y) function.  
[   ]         (   )                                            (3.2) 
 
In this function, p denotes the p-value of the two-sided Wilcoxon Rank-Sum 
test, and h denotes the logical value indicating the decision of the test. The result h = 0 
indicates a failure to reject the null hypothesis at the 5% significance level and h = 1 
indicates the rejection of the null hypothesis.  
3.5.4.2. Student’s t-test 
Student’s t-test is another statistical hypothesis test that can be used to compare 
two populations. It was introduced by William Sealy Gosset. Null hypothesis suggests 
that two populations come from distributions with equal means and equal variances. 
The alternative hypothesis is that the data from two populations have unequal means. 
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The test was implemented in MatLab using ttest2(x,y) function. 
[   ]        (   )                                              (3.3) 
 
In this function, h denotes the test decision and p denotes the p-value of the test. 
The result h = 1 indicates that the null hypothesis is rejected with 5% significance level, 
and results h = 0 indicates otherwise.  
3.5.5. Pathways 
Biochemical pathways provide crucial information on the functions of individual 
genes and proteins. They highlight the systems and processes that contribute to normal 
physiology, as well as disease. Thus, the pathway-level analysis is a powerful approach 
to understand complex biological systems at multiple levels of biological organization 
(Bakir-Gungor et al., 2013). 
 
In order to devise epilepsy-related pathways using the list of genes we generated 
from the methylation dataset, the following pathway analysis approaches were used:   
3.5.5.1. DAVID 
DAVID is a database which includes an integrated biological knowledgebase 
and analytic tools aimed at systematically extracting biological meaning from large 
gene/protein lists (Huang et al., 2009). DAVID is able to visualize genes on pathway 
maps including KEGG, BioCarta, Reactome and Panther pathways. In order to use the 
web-tool, the list of genes is required to be uploaded and DAVID presents related 
results afterwards.  
3.5.5.2. GOrilla 
GOrilla is a web-based application that identifies enriched GO terms in ranked 
lists of genes. In order to use GOrilla, a ranked list of genes is required to be uploaded 
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to the server.  GOrilla visualizes the output of the enrichment analysis as a hierarchical 
structures, therefore it provide a clear view of the relations between enriched GO terms 
(Eden et al., 2009).  
3.5.5.3. KEGG 
Kyoto Encyclopedia of Genes and Genomes (KEGG) is defined as a knowledge 
base for systematic analysis of gene functions, linking genomic information with higher 
order functional information (Kanehisa & Goto, 2000).  The PATHWAY database 
stores the higher order functional information which contains graphical representations 
of cellular processes, such as metabolism, membrane transport, signal transduction and 
cell cycle. The PATHWAY database includes 2706 entries for pathway diagrams 
constructed from 143 manually drawn diagrams. According to Kanehisa and Goto 
(2000), the best organized part of the PATHWAY database is metabolism, which is 
represented by approximately 90 graphical diagrams.  
3.5.6. PANOGA 
3.5.6.1. Definition of the protocol  
PANOGA (Pathway and Network Oriented GWAS Analysis) is a protocol that 
is designed to devise functionally important KEGG pathways through the identification 
of SNP targeted genes within these pathways. The original protocol begins with a list of 
SNPs that found to be associated with disease in Genome-Wide Association Studies 
(GWAS).  
 
The protocol combines evidence from the following sources: i) genetic 
association information obtained through GWAS, ii) SNP functional information, iii) 
protein-protein interaction network, iv) linkage disequilibrium (LD), v) bio-chemical 
pathways. This multidimensional perspective strengthens the methodology (Bakir-
Gungor & Sezerman, 2011).  
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The flow of the protocol is shown in  
Figure 3.1. 
 
 
Figure 3.1 Overview of PANOGA Protocol (Bakir-Gungor et al., 2013) 
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3.5.6.2. Related tools and applications 
3.5.6.2.1. F-SNP 
F-SNP database provides integrated information about the functional effects of 
SNPs obtained from a number of different bioinformatics tools and servers (Lee & 
Shatkay, 2007).  
3.5.6.2.2. SPOT 
SPOT is a web-server for integrating biological databases into the prioritization 
of SNPs for further study after a genome-wide association study (GWAS) (Saccone et 
al., 2010). 
3.5.6.2.3. SNPNexus  
SNPNexus is a web-server that assesses the potential significance of known and 
novel SNPs on the major transcriptome, proteome, regulatory and structural variation 
models in order to identify the phenotypically important variants (Ullah et al., 2012). 
3.5.6.2.4. SNPInfo  
SNPInfo is another web-server that is used to get functional information of SNPs 
(Xu & Taylor, 2009). 
3.5.6.2.5. Cytoscape  
Cytoscape is an open source software platform for visualizing molecular 
interaction networks and biological pathways. It is also used for integrating these 
networks with annotations, gene expression profiles and other state data (Shannon et al., 
2003).  As an open source software platform, Cytoscape allows and encourages to 
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development of plugins that can be integrated into it. Following plugins were used in 
PANOGA. 
3.5.6.2.5.1. jActive Modules  
jActive Modules plugin is used to identify active sub-networks of interacting 
gene products that were also associated with the disease (Ideker et al., 2002). 
3.5.6.2.5.2. ClueGO  
ClueGO plugin is a functional enrichment tool that extracts the non-redundant 
biological information for groups of genes using GO, KEGG and BioCarta ontologies 
(Bindea et al., 2009). Among different ontologies, since KEGG database primarily 
categorizes genes into bona-fide biological pathways; and since biological interpretation 
of pathways is more straightforward compared to GO terms, functional enrichment 
results are only reported using KEGG pathways in PANOGA (Bakir-Gungor & 
Sezerman, 2011).  
3.5.6.2.6. KEGG  
As previously described, the PATHWAY database of KEGG stores functional 
information with graphical representations of cellular processes. In PANOGA protocol, 
most significant 10 pathways are chosen by their p-values, and the information about 
those pathways are uploaded to KEGG PATHWAY web-tool. Visualized results are 
provided and can be saved.  
3.5.6.3. Complete implementation 
PANOGA Protocol requires to access different websites in some of its steps, 
using previous step outputs as next step inputs. For this requirement, the protocol has 
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been automated. The automation both shortened the time that takes to apply the protocol 
and got rid of the errors caused by human interaction.  
 
With the data gathered from listening and analyzing network protocols, POST 
and GET request methods were learned for most of the websites included in the 
protocol. Inputs were given with POST methods and outputs were gathered with GET 
methods.  
 
A problem has arisen for the websites that had complicated request methods and 
used more complex systems that didn't allow for them to be sniffed. Web crawlers were 
used to overcome this problem as to simulate a real user browsing and using those 
websites. 
 
For various steps of this protocol, software was developed with different 
working conditions and in different programming languages. In order to provide steps 
working flawlessly with each other, all software was re-implemented in Java with 
necessary upgrades.  
 
The software supports working with multiple threads, so it's possible to have 
more than one active run theoretically. Yet, the final steps of the protocol require all 
available resources of the computer and also include the step that has the longest 
computation time amongst all the steps. Because of this bottleneck, the software uses 
only one thread at the moment. 
 
The software also records its progress into separate log files. A simpler log file is 
used to notify the owner of the current run, and a detailed log file is also used to track 
the software from a developer’s point of view. 
 
The protocol also required for local software to use the obtained data from 
websites, so the developed software was not only automated the flow between websites 
but also set the software up with the required inputs and parameters. 
 
For a user to use this protocol from web, this software was put inside a 
webserver and a website to use this protocol has been generated in PHP. The website 
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takes user inputs to record them into a database and it also takes the user files to be 
uploaded into the server. The software periodically checks whether new entries are 
made and works through the protocol when it detects a new entry. The website also 
generates a unique id and unique link for the user to check their status by reading log 
files mentioned above. With this way, the database provides the record of all the 
protocol runs made by the website. The website is also used for contacting and giving 
brief information about the protocol itself. 
 
A Linux based web host with terminal access was the first candidate for Panoga 
Protocol. First implementation and the tests for the website and the software were 
carried out in this environment. The developed software had no problems regarding 
Linux. But as Cytospace is a commercial product, although it supports working through 
command line with some alterations, the necessary add-ons used in the protocol did not; 
so web based hosting wasn’t holding the requirements. 
 
A Windows based virtual private server was the second candidate. With the 
experience from the first candidate, the system was transferred and started working 
quickly, and the results were satisfying. A complete run of the protocol has been 
initiated successfully, and the website was made online. 
3.5.6.4. Partial use  
Since PANOGA Protocol begins with a list of SNPs and makes use of their 
functional information, it wasn’t a viable tool for devising functionally important 
pathways from a list of genes. On the other hand, we were able to skip the steps that are 
related to SNPs, and proceed with gene information only with small modifications in 
the code. It was also necessary to perform a calculation to determine significance score 
for each gene to provide ranking information for the network in jActive Modules. 
Methylation β values for the individuals from a family trio on the CpG locus that is 
associated with the chosen gene are used in the calculation of a score. Because of the 
fact that two different list of genes were generated using different information regarding 
methylation, it was also required to devise two different calculation methods. 
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Considering β value having a direct correspondence with methylation, the score 
calculations in Table 3.3 are applied. 
 
First approach ((Offspring – 0.5) + (Parent – 0.5) + (0.5 – Control)) / 1.5 
Second approach ((0.5 – Offspring) + (0.5 – Parent) + (Control – 0.5)) / 1.5 
Table 3.3 Offspring: β value for the offspring on a locus, Parent: β value for the parent 
with disorder on a locus, Control: β value for the control parent on a locus 
 
If more than one CpG loci are associated with a gene, only the highest score is 
used. 
 
The flow of our approach begins with jActive Modules step, which identifies 
active sub-networks of interacting gene products, and continues with the protocol until 
the end where the important KEGG pathways are identified. The most significant 10 
pathways are chosen according to their p-values, and their information are used for 
KEGG pathway identification.  
3.5.7. Promoter Analysis 
Since DNA methylation in promoter regions is considered crucial, its analysis is 
necessary to provide understanding about relationships between DNA methylation, gene 
expression and underlying pathways related to a disease. Therefore, we expected the 
results of promoter analysis to be more significant than a general analysis, and focused 
on promoter analysis while repeating each step for general analysis. 
 
Illumina categorizes probes into six gene feature groups, namely TSS1500 
(within 1500 bps of a transcription start site (TSS)), TSS200 (within 200 bps of a TSS), 
5’UTR (5’ untranslated region), first exon, body and 3’UTR (3’ untranslated region). 
Manifest file of HumanMethylation450 Bead Chip provides information about the 
groups of CpG loci.  
 
In order to accomplish a promoter based analysis, we determined CpG loci 
which belong to TSS1500 and TSS200 groups. We generated lists of genes only from 
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those CpG loci and applied all three filters separately and repeated the remaining parts 
of our analysis.  
3.5.8. Normalization 
Illumina Infinium HumanMethylation450 Bead Chip arrays include two 
different probe design types. Since some percentage of CpG loci are associated with 
type1 and the rest are associated with type2, it may result in biased conclusions in 
methylation analysis. In order to remove this bias, a normalization process may be 
required. 
 
In this study, Beta-Mixture Quantile Normalization (BMIQ) is applied for 
normalization and its results are presented separately. BMIQ applies a normalization 
strategy that adjusts the β values of type2 design probes into a statistical distribution 
characteristic of type1 probes (Teschendorff et al., 2013). The method is presented in R 
language, and in this study, it was applied using R Software which is a free software 
environment for statistical computing.  
3.5.9. Quality Checking 
In the methylation dataset, three of the samples which were gathered from 
microarray analysis by HumanMethylation450 Bead Chip have non-satisfactory quality. 
The samples of the affected parent in family trios 4 and 7 have low signal intensities 
and the sample of the child in family trio 7 had difficulties in the bisulfite conversion 
step. Therefore, samples of family trio 4 and family trio 7 were removed from dataset 
and a few runs were repeated to check the effects of the removed data.  
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CHAPTER 4 
Results 
  
4.1. CpG Island Nucleotide Composition Determination 
Common motifs around methylated and unmethylated CpG islands were 
determined. Most common motifs are chosen according to their frequencies and 
common motifs that have at least 0.1 difference in frequency are presented in Table 4.1.  
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Table 4.1 List of common motifs around methylated (a) and unmethylated (b) CpG 
islands for different window sizes 
4.2. Application of First Filter 
Firstly, results of the analysis without any filters are presented in APPENDIX A. 
 
After applying the first filter which removes probes with no β value, all rs and ch 
probes, all sex chromosome probes and autosomal probes with sex differences; we 
gathered pathway analysis results also from partial implementation of PANOGA 
protocol as well as David and Gorilla.  
4.2.1. General Results 
4.2.1.1. DAVID results 
Detailed results for the analysis with application of first filter on DAVID are 
shown in APPENDIX B. Most frequently devised pathways and the number of families 
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they are found are presented in Table 4.2 and Table 4.3 for KEGG, Table 4.4 and Table 
4.5 for BioCarta, Table 4.6 and Table 4.7 for Panther, Table 4.8 and Table 4.9 for 
Reactome.  
 
 
KEGG Pathways Count 
hsa04514:Cell adhesion molecules (CAMs) 5 
hsa04612:Antigen processing and presentation 5 
hsa05310:Asthma 4 
hsa05332:Graft-versus-host disease 4 
hsa05320:Autoimmune thyroid disease 4 
hsa05322:Systemic lupus erythematosus 4 
hsa05330:Allograft rejection 4 
hsa04672:Intestinal immune network for IgA production 4 
hsa04940:Type I diabetes mellitus 4 
hsa05416:Viral myocarditis 4 
hsa04530:Tight junction 3 
hsa04640:Hematopoietic cell lineage 3 
hsa04916:Melanogenesis 2 
hsa04080:Neuroactive ligand-receptor interaction 2 
hsa04310:Wnt signaling pathway 2 
hsa04510:Focal adhesion 2 
hsa04810:Regulation of actin cytoskeleton 2 
hsa04270:Vascular smooth muscle contraction 2 
hsa03440:Homologous recombination 2 
hsa05200:Pathways in cancer 2 
hsa04020:Calcium signaling pathway 2 
hsa04650:Natural killer cell mediated cytotoxicity 2 
Table 4.2 Number of KEGG pathways (first approach/first filter) 
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KEGG Pathways Count 
hsa04672:Intestinal immune network for IgA production 6 
hsa05320:Autoimmune thyroid disease 5 
hsa04940:Type I diabetes mellitus 5 
hsa04514:Cell adhesion molecules (CAMs) 5 
hsa05416:Viral myocarditis 5 
hsa04612:Antigen processing and presentation 5 
hsa05310:Asthma 5 
hsa05322:Systemic lupus erythematosus 5 
hsa05332:Graft-versus-host disease 5 
hsa05330:Allograft rejection 5 
hsa04740:Olfactory transduction 4 
hsa05200:Pathways in cancer 3 
hsa04530:Tight junction 3 
hsa04310:Wnt signaling pathway 3 
hsa04510:Focal adhesion 3 
hsa04010:MAPK signaling pathway 3 
hsa04070:Phosphatidylinositol signaling system 3 
hsa04650:Natural killer cell mediated cytotoxicity 3 
hsa04666:Fc gamma R-mediated phagocytosis 3 
hsa04370:VEGF signaling pathway 2 
hsa05214:Glioma 2 
hsa05130:Pathogenic Escherichia coli infection 2 
hsa04720:Long-term potentiation 2 
hsa04640:Hematopoietic cell lineage 2 
hsa04730:Long-term depression 2 
hsa00512:O-Glycan biosynthesis 2 
hsa04144:Endocytosis 2 
hsa04270:Vascular smooth muscle contraction 2 
hsa04912:GnRH signaling pathway 2 
hsa05223:Non-small cell lung cancer 2 
hsa04916:Melanogenesis 2 
hsa04012:ErbB signaling pathway 2 
hsa04540:Gap junction 2 
hsa04020:Calcium signaling pathway 2 
hsa04960:Aldosterone-regulated sodium reabsorption 2 
hsa05110:Vibrio cholerae infection 2 
hsa04670:Leukocyte transendothelial migration 2 
hsa04664:Fc epsilon RI signaling pathway 2 
Table 4.3 Number of KEGG pathways (second approach/first filter) 
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BioCarta Pathways Count 
h_il5Pathway:IL 5 Signaling Pathway 3 
h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation 3 
h_mhcPathway:Antigen Processing and Presentation 3 
h_asbcellPathway:Antigen Dependent B Cell Activation 3 
h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of 
Allergy 3 
h_bbcellPathway:Bystander B Cell Activation 3 
h_inflamPathway:Cytokines and Inflammatory Response 3 
h_blymphocytePathway:B Lymphocyte Cell Surface Molecules 3 
h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation 3 
h_CSKPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor 3 
h_th1th2Pathway:Th1/Th2 Differentiation 3 
h_metPathway:Signaling of Hepatocyte Growth Factor Receptor 2 
h_integrinPathway:Integrin Signaling Pathway 2 
Table 4.4 Number of BioCarta pathways (first approach/first filter) 
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BioCarta Pathways Count 
h_inflamPathway:Cytokines and Inflammatory Response 3 
h_TPOPathway:TPO Signaling Pathway 3 
h_biopeptidesPathway:Bioactive Peptide Induced Signaling Pathway 3 
h_ghPathway:Growth Hormone Signaling Pathway 3 
h_myosinPathway:PKC-catalyzed phosphorylation of inhibitory 
phosphoprotein of myosin phosphatase 2 
h_vegfPathway:VEGF, Hypoxia, and Angiogenesis 2 
h_pyk2Pathway:Links between Pyk2 and Map Kinases 2 
h_bcrPathway:BCR Signaling Pathway 2 
h_ionPathway:Ion Channel and Phorbal Esters Signaling Pathway 2 
h_arenrf2Pathway:Oxidative Stress Induced Gene Expression Via Nrf2 2 
h_pkcPathway:Activation of PKC through G protein coupled receptor 2 
h_blymphocytePathway:B Lymphocyte Cell Surface Molecules 2 
h_tcrPathway:T Cell Receptor Signaling Pathway 2 
h_calcineurinPathway:Effects of calcineurin in Keratinocyte Differentiation 2 
h_il5Pathway:IL 5 Signaling Pathway 2 
h_cardiacegfPathway:Role of EGF Receptor Transactivation by GPCRs in 
Cardiac Hypertrophy 2 
h_mef2dPathway:Role of MEF2D in T-cell Apoptosis 2 
h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors 2 
h_Par1Pathway:Thrombin signaling and protease-activated receptors 2 
h_CCR3Pathway:CCR3 signaling in Eosinophils 2 
h_plcPathway:Phospholipase C Signaling Pathway 2 
h_Ccr5Pathway:Pertussis toxin-insensitive CCR5 Signaling in Macrophage 2 
h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha 2 
h_cdMacPathway:Cadmium induces DNA synthesis and proliferation in 
macrophages 2 
h_bbcellPathway:Bystander B Cell Activation 2 
h_chemicalPathway:Apoptotic Signaling in Response to DNA Damage 2 
h_agpcrPathway:Attenuation of GPCR Signaling 2 
h_crebPathway:Transcription factor CREB and its extracellular signals 2 
h_At1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 
dependent signaling 2 
h_CSKPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor 2 
h_keratinocytePathway:Keratinocyte Differentiation 2 
h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation 2 
h_mhcPathway:Antigen Processing and Presentation 2 
h_cxcr4Pathway:CXCR4 Signaling Pathway 2 
h_nos1Pathway:Nitric Oxide Signaling Pathway 2 
h_edg1Pathway:Phospholipids as signalling intermediaries 2 
h_pdgfPathway:PDGF Signaling Pathway 2 
h_egfPathway:EGF Signaling Pathway 2 
h_plcdPathway:Phospholipase C d1 in phospholipid associated cell signaling 2 
h_eif4Pathway:Regulation of eIF4e and p70 S6 Kinase 2 
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h_pparaPathway:Mechanism of Gene Regulation by Peroxisome Proliferators 
via PPARa(alpha) 2 
h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of 
Allergy 2 
h_sppaPathway:Aspirin Blocks Signaling Pathway Involved in Platelet 
Activation 2 
h_erbB4pathway:g-Secretase mediated ErbB4 Signaling Pathway 2 
h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation 2 
h_th1th2Pathway:Th1/Th2 Differentiation 2 
h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality 2 
h_gpcrPathway:Signaling Pathway from G-Protein Families 2 
h_asbcellPathway:Antigen Dependent B Cell Activation 2 
h_trkaPathway:Trka Receptor Signaling Pathway 2 
Table 4.5 Number of BioCarta pathways (second approach/first filter) 
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Panther Pathways Count 
P00057:Wnt signaling pathway 4 
P00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha 
mediated pathway 4 
P00031:Inflammation mediated by chemokine and cytokine signaling pathway 3 
P00049:Parkinson disease 3 
P00047:PDGF signaling pathway 3 
P00010:B cell activation 3 
P00012:Cadherin signaling pathway 3 
P00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha 
mediated pathway 3 
P00042:Muscarinic acetylcholine receptor 1 and 3 signaling pathway 2 
P00002:Alpha adrenergic receptor signaling pathway 2 
P00019:Endothelin signaling pathway 2 
P00053:T cell activation 2 
P00041:Metabotropic glutamate receptor group I pathway 2 
P00056:VEGF signaling pathway 2 
P00018:EGF receptor signaling pathway 2 
P04374:5HT2 type receptor mediated signaling pathway 2 
P00021:FGF signaling pathway 2 
P00006:Apoptosis signaling pathway 2 
P00003:Alzheimer disease-amyloid secretase pathway 2 
P04385:Histamine H1 receptor mediated signaling pathway 2 
P00005:Angiogenesis 2 
P04391:Oxytocin receptor mediated signaling pathway 2 
P04394:Thyrotropin-releasing hormone receptor signaling pathway 2 
P00029:Huntington disease 2 
P00034:Integrin signalling pathway 2 
P05911:Angiotensin II-stimulated signaling through G proteins and beta-
arrestin 2 
Table 4.6 Number of Panther pathways (first approach/first filter) 
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Panther Pathways Count 
P00053:T cell activation 6 
P00057:Wnt signaling pathway 4 
P04394:Thyrotropin-releasing hormone receptor signaling pathway 3 
P00003:Alzheimer disease-amyloid secretase pathway 3 
P00042:Muscarinic acetylcholine receptor 1 and 3 signaling pathway 3 
P00005:Angiogenesis 3 
P04385:Histamine H1 receptor mediated signaling pathway 3 
P00006:Apoptosis signaling pathway 3 
P00041:Metabotropic glutamate receptor group I pathway 3 
P00010:B cell activation 3 
P00047:PDGF signaling pathway 3 
P00018:EGF receptor signaling pathway 3 
P00056:VEGF signaling pathway 3 
P00019:Endothelin signaling pathway 3 
P04374:5HT2 type receptor mediated signaling pathway 3 
P00021:FGF signaling pathway 3 
P04391:Oxytocin receptor mediated signaling pathway 3 
P00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha 
mediated pathway 3 
P05911:Angiotensin II-stimulated signaling through G proteins and beta-
arrestin 3 
P00031:Inflammation mediated by chemokine and cytokine signaling pathway 3 
P00002:Alpha adrenergic receptor signaling pathway 3 
P00029:Huntington disease 2 
Table 4.7 Number of Panther pathways (second approach/first filter) 
 
 
Reactome Pathways Count 
REACT_14797:Signaling by GPCR 3 
REACT_6900:Signaling in Immune system 3 
REACT_71:Gene Expression 2 
Table 4.8 Number of Reactome pathways (first approach/first filter) 
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Reactome Pathways Count 
REACT_6900:Signaling in Immune system 5 
REACT_604:Hemostasis 3 
REACT_14797:Signaling by GPCR 3 
REACT_15380:Diabetes pathways 3 
REACT_13685:Synaptic Transmission 2 
REACT_17015:Metabolism of proteins 2 
Table 4.9 Number of Reactome pathways (second approach/first filter) 
4.2.1.2. PANOGA results 
Even though PANOGA partial implementation did not yield any results for 
family trios separately with first filter applied, when we combined the lists of genes of 
each family trio, the results in Table 4.10, Table 4.12 and Table 4.12 are obtained.  
 
First Approach 
Metabolic pathways 
Pathways in cancer 
Cell cycle 
Neurotrophin signaling pathway 
MAPK signaling pathway 
Regulation of actin cytoskeleton 
Insulin signaling pathway 
Ribosome 
ErbB signaling pathway 
Apoptosis 
Table 4.10 PANOGA results of general analysis with first filter (first approach) 
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Second Approach 
Complement and coagulation cascades 
Cholinergic synapse 
GABAergic synapse 
Retrograde endocannabinoid signaling 
TGF-beta signaling pathway 
Type II diabetes mellitus 
Aldosterone-regulated sodium reabsorption 
Bacterial invasion of epithelial cells 
Glioma 
Citrate cycle (TCA cycle) 
Table 4.11 PANOGA results of general analysis with first filter (second approach) 
 
Third Approach 
Cell cycle 
Chemokine signaling pathway 
Ribosome 
Glutamatergic synapse 
Cholinergic synapse 
TGF-beta signaling pathway 
Retrograde endocannabinoid signaling 
Insulin signaling pathway 
Renal cell carcinoma 
Long-term potentiation 
Table 4.12 PANOGA results of general analysis with first filter (third approach) 
 
4.2.2. Promoter Results 
4.2.2.1. DAVID results 
Detailed results for the analysis for promoter region with application of first 
filter on DAVID are shown in APPENDIX B. Most frequently devised pathways and 
the number of families they are found are presented in Table 4.13 and Table 4.14 for 
KEGG, Table 4.15 for Panther, Table 4.16 and Table 4.17 for Reactome. Most 
frequently found pathways for BioCarta are not reported for this analysis, because none 
of the families were found in more than one family. 
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KEGG Pathways Count 
hsa05322:Systemic lupus erythematosus 2 
hsa05310:Asthma 2 
hsa05332:Graft-versus-host disease 2 
hsa04080:Neuroactive ligand-receptor interaction 2 
hsa05320:Autoimmune thyroid disease 2 
hsa04514:Cell adhesion molecules (CAMs) 2 
hsa05330:Allograft rejection 2 
hsa04612:Antigen processing and presentation 2 
hsa05416:Viral myocarditis 2 
hsa04940:Type I diabetes mellitus 2 
hsa04672:Intestinal immune network for IgA production 2 
Table 4.13 Number of KEGG pathways in promoter analysis (first approach/first filter) 
 
KEGG Pathways Count 
hsa04740:Olfactory transduction 4 
Table 4.14 Number of KEGG pathways in promoter analysis (second approach/first 
filter) 
 
Panther Pathways Count 
P00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha 
mediated pathway 2 
P00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha 
mediated pathway 2 
Table 4.15 Number of Panther pathways in promoter analysis (first approach/first filter) 
 
Reactome Pathways Count 
REACT_14797:Signaling by GPCR 3 
Table 4.16 Number of Reactome pathways in promoter analysis (first approach/first 
filter) 
 
Reactome Pathways Count 
REACT_14797:Signaling by GPCR 3 
Table 4.17 Number of Reactome pathways in promoter analysis (second approach/first 
filter) 
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4.2.2.2. PANOGA results 
 Even though PANOGA partial implementation did not yield any results for 
family trios separately with first filter applied, when we combined the lists of genes of 
each family trio, the results in Table 4.18, Table 4.19 and Table 4.20 are obtained.  
 
First Approach 
Pathways in cancer 
Spliceosome 
Chemokine signaling pathway 
Cell cycle 
Neurotrophin signaling pathway 
Ribosome 
Focal adhesion 
Proteasome 
T cell receptor signaling pathway 
Chronic myeloid leukemia 
Table 4.18 PANOGA results of promoter analysis with first filter (first approach) 
 
Second Approach 
Pathways in cancer 
Spliceosome 
Chemokine signaling pathway 
Cell cycle 
Neurotrophin signaling pathway 
Ribosome 
Focal adhesion 
Proteasome 
T cell receptor signaling pathway 
Chronic myeloid leukemia 
Table 4.19 PANOGA results of promoter analysis with first filter (second approach) 
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Third Approach 
Cell cycle 
Nucleotide excision repair 
Chemokine signaling pathway 
Ribosome 
Complement and coagulation cascades 
Glutamatergic synapse 
Cholinergic synapse 
TGF-beta signaling pathway 
Retrograde endocannabinoid signaling 
Proteasome 
Table 4.20 PANOGA results of promoter analysis with first filter (third approach) 
4.3. Application of Second Filter 
After the results of first filter are gathered, we applied the second filter which 
removes cross-reactive probes and polymorphic CpGs. 
4.3.1. General Results 
4.3.1.1. DAVID results 
Detailed results for the analysis with application of second filter on DAVID are 
shown in APPENDIX B. Most frequently devised pathways and the number of families 
they are found are presented in Table 4.21 and Table 4.22 for KEGG, Table 4.23 and 
Table 4.24 for BioCarta, Table 4.25 and Table 4.26 for Panther, Table 4.27 and Table 
4.28 for Reactome.  
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KEGG Pathways Count 
hsa05322:Systemic lupus erythematosus 3 
hsa05310:Asthma 3 
hsa05332:Graft-versus-host disease 3 
hsa04514:Cell adhesion molecules (CAMs) 3 
hsa05320:Autoimmune thyroid disease 3 
hsa04612:Antigen processing and presentation 3 
hsa05330:Allograft rejection 3 
hsa04672:Intestinal immune network for IgA production 3 
hsa05416:Viral myocarditis 3 
hsa04940:Type I diabetes mellitus 3 
hsa04530:Tight junction 2 
hsa04640:Hematopoietic cell lineage 2 
Table 4.21 Number of KEGG pathways (first approach/second filter) 
 
KEGG Pathways Count 
hsa04740:Olfactory transduction 3 
hsa04672:Intestinal immune network for IgA production 2 
Table 4.22 Number of KEGG pathways (second approach/second filter) 
 
BioCarta Pathways Count 
h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation 2 
h_asbcellPathway:Antigen Dependent B Cell Activation 2 
h_ctla4Pathway:The Co-Stimulatory Signal During T-cell Activation 2 
h_bbcellPathway:Bystander B Cell Activation 2 
h_mhcPathway:Antigen Processing and Presentation 2 
h_blymphocytePathway:B Lymphocyte Cell Surface Molecules 2 
h_th1th2Pathway:Th1/Th2 Differentiation 2 
h_CSKPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor 2 
h_eosinophilsPathway:The Role of Eosinophils in the Chemokine Network of 
Allergy 2 
Table 4.23 Number of BioCarta pathways (first approach/second filter) 
 
BioCarta Pathways Count 
h_inflamPathway:Cytokines and Inflammatory Response 2 
Table 4.24 Number of BioCarta pathways (second approach/second filter) 
 
 
 
 
  
43 
Panther Pathways Count 
P00057:Wnt signaling pathway 3 
P00012:Cadherin signaling pathway 2 
Table 4.25 Number of Panther pathways (first approach/second filter) 
 
Panther Pathways Count 
P00057:Wnt signaling pathway 2 
Table 4.26 Number of Panther pathways (second approach/second filter) 
 
Reactome Pathways Count 
REACT_6900:Signaling in Immune system 3 
REACT_14797:Signaling by GPCR 2 
Table 4.27 Number of Reactome pathways (first approach/second filter) 
 
Reactome Pathways Count 
REACT_14797:Signaling by GPCR 3 
Table 4.28 Number of Reactome pathways (second approach/second filter) 
4.3.1.2. PANOGA results 
Even though PANOGA partial implementation did not yield any results for 
family trios separately with first filter applied, when we combined the lists of genes of 
each family trio, the results in Table 4.29, Table 4.30 and Table 4.31 are obtained.  
 
First Approach 
Pathways in cancer 
Chronic myeloid leukemia 
Spliceosome 
Neurotrophin signaling pathway 
Focal adhesion 
Ribosome 
ErbB signaling pathway 
Proteasome 
Cell cycle 
T cell receptor signaling pathway 
Table 4.29 PANOGA results of general analysis with second filter (first approach) 
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Second Approach 
Proteasome 
Ribosome 
Circadian rhythm 
Homologous recombination 
Pathogenic Escherichia coli infection 
Shigellosis 
Complement and coagulation cascades 
Bacterial invasion of epithelial cells 
Pancreatic cancer 
GABAergic synapse 
Table 4.30 PANOGA results of general analysis with second filter (second approach) 
 
Third Approach 
Pathways in cancer 
Cell cycle 
Nucleotide excision repair 
Neurotrophin signaling pathway 
Chemokine signaling pathway 
Ribosome 
Chronic myeloid leukemia 
Adherens junction 
Complement and coagulation cascades 
Prostate cancer 
Table 4.31 PANOGA results of general analysis with second filter (third approach) 
4.3.2. Promoter Results 
4.3.2.1. DAVID results 
Detailed results for analysis for promoter region with application of second filter 
on DAVID are shown in APPENDIX B. Most frequently devised pathways and the 
number of families they are found are presented in Table 4.32 for KEGG, Table 4.33 
and Table 4.34 for Reactome. Rest of the results is not presented here, because none of 
the families were found in more than one family.  
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KEGG Pathways Count 
hsa04740:Olfactory transduction 2 
Table 4.32 Number of KEGG pathways in promoter analysis (second approach/second 
filter) 
 
Reactome Pathways Count 
REACT_14797:Signaling by GPCR 2 
Table 4.33 Number of Reactome pathways in promoter analysis (first approach/second 
filter) 
 
Reactome Pathways Count 
REACT_14797:Signaling by GPCR 2 
Table 4.34 Number of Reactome pathways in promoter analysis (second  
approach/second filter) 
4.3.2.2. PANOGA results 
Even though PANOGA partial implementation did not yield any results for 
family trios separately with second filter applied, when we combined the lists of genes 
of each family trio, the results in Table 4.35, Table 4.36 and Table 4.37 are obtained. 
 
First Approach 
Pathways in cancer 
Cell cycle 
Neurotrophin signaling pathway 
Focal adhesion 
Chronic myeloid leukemia 
Spliceosome 
HTLV-I infection 
Prostate cancer 
Glioma 
Long-term potentiation 
Table 4.35 PANOGA results of promoter analysis with second filter (first approach) 
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Second Approach 
Pathways in cancer 
Cell cycle 
Neurotrophin signaling pathway 
Focal adhesion 
Chronic myeloid leukemia 
Spliceosome 
HTLV-I infection 
Prostate cancer 
Glioma 
Long-term potentiation 
Table 4.36 PANOGA results of promoter analysis with second filter (second approach) 
 
Third Approach 
Pathways in cancer 
Cell cycle 
Nucleotide excision repair 
Neurotrophin signaling pathway 
Chemokine signaling pathway 
Ribosome 
Chronic myeloid leukemia 
Adherens junction 
Complement and coagulation cascades 
Prostate cancer 
Table 4.37 PANOGA results of promoter analysis with second filter (third approach) 
4.4. Results of the Analysis with Normalization 
Beta-mixture quantile normalization was applied to the data and pathway results 
were gathered from PANOGA.  
4.4.1. General Results 
Pathway results of the data pool which includes data from all families are 
gathered with PANOGA, and they are presented in Table 4.38. Most common pathways 
are presented in Table 4.39 and Table 4.40 with the number of families they are found.  
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First Filter Second Filter 
Spliceosome Proteasome 
Ribosome TGF-beta signaling pathway 
Pathways in cancer Complement and coagulation cascades 
Complement and coagulation cascades ECM-receptor interaction 
Cell cycle Ribosome 
Neurotrophin signaling pathway Notch signaling pathway 
Focal adhesion Chronic myeloid leukemia 
TGF-beta signaling pathway Type II diabetes mellitus 
T cell receptor signaling pathway Protein digestion and absorption 
ErbB signaling pathway Homologous recombination 
Table 4.38 Normalization results of general analysis (third approach) 
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Pathways Count 
Chronic myeloid leukemia 8 
Neurotrophin signaling pathway 7 
Pathways in cancer 7 
T cell receptor signaling pathway 7 
Ribosome 6 
Focal adhesion 5 
Cell cycle 5 
ErbB signaling pathway 5 
HTLV-I infection 5 
Spliceosome 3 
Glutamatergic synapse 3 
GABAergic synapse 3 
Retrograde endocannabinoid signaling 2 
Cholinergic synapse 2 
Non-small cell lung cancer 2 
RNA polymerase 1 
Prostate cancer 1 
Type II diabetes mellitus 1 
Endometrial cancer 1 
Adherens junction 1 
Acute myeloid leukemia 1 
Cytosolic DNA-sensing pathway 1 
MAPK signaling pathway 1 
Propanoate metabolism 1 
Measles 1 
Proteasome 1 
Citrate cycle (TCA cycle) 1 
Complement and coagulation cascades 1 
Endocytosis 1 
Epithelial cell signaling in Helicobacter pylori infection 1 
Notch signaling pathway 1 
TGF-beta signaling pathway 1 
Pancreatic cancer 1 
Glioma 1 
Colorectal cancer 1 
Table 4.39 Most common pathways for general analysis with first filter (third approach) 
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Pathways Count 
Proteasome 3 
RNA degradation 2 
Notch signaling pathway 2 
Type II diabetes mellitus 2 
Circadian rhythm 2 
Allograft rejection 2 
Pentose phosphate pathway 2 
Complement and coagulation cascades 2 
TGF-beta signaling pathway 2 
GABAergic synapse 2 
Aldosterone-regulated sodium reabsorption 2 
Type I diabetes mellitus 1 
Staphylococcus aureus infection 1 
Amphetamine addiction 1 
Asthma 1 
Homologous recombination 1 
Folate biosynthesis 1 
Intestinal immune network for IgA production 1 
Autoimmune thyroid disease 1 
Graft-versus-host disease 1 
Table 4.40 Most common pathways for general analysis with second filter (third 
approach) 
 
4.4.2. Promoter Results 
Pathway results of the data pool which includes data from all families are 
gathered with PANOGA, and they are presented in Table 4.41. Most common pathways 
are presented in Table 4.42 and Table 4.43 with the number of families they are found. 
 
 
 
 
 
 
 
  
50 
First Filter Second Filter 
Complement and coagulation cascades Complement and coagulation cascades 
Neurotrophin signaling pathway Notch signaling pathway 
Pathways in cancer Proteasome 
Cell cycle B cell receptor signaling pathway 
Chronic myeloid leukemia Acute myeloid leukemia 
Prostate cancer Malaria 
T cell receptor signaling pathway 
Endocrine and other factor-regulated calcium 
reabsorption 
Ribosome Aldosterone-regulated sodium reabsorption 
Insulin signaling pathway RNA polymerase 
Glioma Folate biosynthesis 
Table 4.41 Normalization results of promoter analysis (third approach) 
 
Pathways Count 
T cell receptor signaling pathway 3 
Pancreatic cancer 3 
Neurotrophin signaling pathway 3 
Chronic myeloid leukemia 3 
Pathways in cancer 3 
Endocytosis 3 
Focal adhesion 3 
Cholinergic synapse 2 
Ribosome 2 
Complement and coagulation cascades 2 
Adherens junction 1 
Base excision repair 1 
DNA replication 1 
Mismatch repair 1 
Prostate cancer 1 
ErbB signaling pathway 1 
Homologous recombination 1 
Nucleotide excision repair 1 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 1 
Table 4.42 Most common pathways for promoter analysis with first filter (third 
approach) 
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Pathways Count 
Glutamatergic synapse 1 
Renin-angiotensin system 1 
Notch signaling pathway 1 
Complement and coagulation cascades 1 
Cholinergic synapse 1 
DNA replication 1 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 1 
Dopaminergic synapse 1 
Proteasome 1 
ECM-receptor interaction 1 
Retrograde endocannabinoid signaling 1 
Folate biosynthesis 1 
GABAergic synapse 1 
Table 4.43 Most common pathways for promoter analysis with second filter (third 
approach) 
4.5. Results of the Quality Checking 
4.5.1. Results without Normalization 
General and promoter analysis results from PANOGA with third approach are 
presented in Table 4.44. Second filter was applied in this analysis.  
General Analysis Promoter Analysis 
Nucleotide excision repair Hedgehog signaling pathway 
Ribosome   
DNA replication   
Mismatch repair   
Base excision repair   
Non-homologous end-joining   
Proteasome   
Thyroid cancer   
Homologous recombination   
Circadian rhythm   
Table 4.44 General and promoter analysis results without normalization 
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4.5.2. Results with Normalization 
General analysis results from PANOGA with third approach are presented in 
Table 4.45. Second filter was applied in this analysis.  Promoter analysis did not yield 
any results for this case. 
General Analysis 
Neurotrophin signaling pathway 
Pathways in cancer 
T cell receptor signaling pathway 
Endocytosis 
Pancreatic cancer 
Focal adhesion 
Chronic myeloid leukemia 
Adherens junction 
ErbB signaling pathway 
Prostate cancer 
Table 4.45 General and promoter analysis results with normalization 
 
4.6. Results of the Statistical Analysis 
In order to determine whether there is a significant difference in methylation 
levels for individuals that have a different status in terms of being affected by the 
disorder, we applied a statistical analysis using Wilcoxon Rank-Sum Test and Student’s 
t-test.  
 
Initially we calculated the average, standard deviation and variance of 
methylation levels of each individual. Averages of those values are also calculated for 
each group (offspring, affected parent, control parent). Results for each group are shown 
in Table 4.46, Table 4.47 and Table 4.48 respectively. 
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Table 4.46 Variance, standard deviation and average values for offsprings. 
 
  Variance Std. Deviation Average 
Family trio 1 0,13 0,36 0,50 
Family trio 2 0,13 0,36 0,50 
Family trio 3 0,13 0,36 0,50 
Family trio 4 0,09 0,30 0,51 
Family trio 5 0,14 0,37 0,50 
Family trio 6 0,13 0,36 0,50 
Family trio 7 0,08 0,29 0,45 
Family trio 8 0,13 0,36 0,50 
Family trio 9 0,13 0,37 0,51 
Family trio 10 0,14 0,37 0,51 
Average 0,12 0,35 0,50 
Table 4.47 Variance, standard deviation and average values for affected parents. 
 
  Variance Std. Deviation Average 
Family trio 1 0,13 0,36 0,51 
Family trio 2 0,13 0,36 0,50 
Family trio 3 0,13 0,37 0,51 
Family trio 4 0,13 0,37 0,51 
Family trio 5 0,13 0,36 0,50 
Family trio 6 0,13 0,36 0,50 
Family trio 7 0,13 0,36 0,51 
Family trio 8 0,13 0,36 0,50 
Family trio 9 0,13 0,36 0,51 
Family trio 10 0,14 0,37 0,51 
Average 0,13 0,36 0,50 
Table 4.48 Variance, standard deviation and average values for control parents. 
  Variance Std. Deviation Average 
Family trio 1 0,14 0,37 0,51 
Family trio 2 0,13 0,36 0,50 
Family trio 3 0,13 0,36 0,51 
Family trio 4 0,14 0,37 0,50 
Family trio 5 0,14 0,37 0,49 
Family trio 6 0,13 0,37 0,51 
Family trio 7 0,13 0,35 0,50 
Family trio 8 0,13 0,36 0,50 
Family trio 9 0,13 0,36 0,51 
Family trio 10 0,14 0,37 0,52 
Average 0,13 0,36 0,51 
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Then we applied Wilcoxon Rank-Sum Test and Student’s t-test with the null 
hypothesis being ―the difference between two samples has no significance‖. 
Comparisons were made between offspring versus control parent, affected parent versus 
control parent and all affected samples (offspring and affected parent) versus control 
parent. Results for both tests are shown in Table 4.49.  
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Test Results 
All  
families 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00592  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,20959  h = 0 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Family 
No.1 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,01426  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Family 
No.2 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Family 
No.3 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,87041  h = 0 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,66145  h = 0 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00106  h = 1 
Family 
No.4 
All affected (child&parent) vs. Control 
Wilcoxon 0,00313  h = 1 
Student's t-test 0,58478  h = 0 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00003  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,30672  h = 0 
Student's t-test 0,00019  h = 1 
Family 
No.5 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00053  h = 1 
Family 
No.6 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00103  h = 1 
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Family 
No.7 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00188  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Family 
No.8 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Child vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00000  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,00567  h = 1 
Family 
No.9 
All affected (child&parent) vs. Control 
Wilcoxon 0,35086  h = 0 
Student's t-test 0,91461  h = 0 
Affected Child vs. Control 
Wilcoxon 0,26554  h = 0 
Student's t-test 0,47038  h = 0 
Affected Parent vs. Control 
Wilcoxon 0,00125  h = 1 
Student's t-test 0,00480  h = 1 
Family 
No.10 
All affected (child&parent) vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,01864  h = 1 
Affected Child vs. Control 
Wilcoxon 0,65677  h = 0 
Student's t-test 0,00028  h = 1 
Affected Parent vs. Control 
Wilcoxon 0,00000  h = 1 
Student's t-test 0,88178  h = 0 
Table 4.49 Results of the statistical analysis. Null hypothesis for both methods states 
―the difference between two samples has no importance‖, therefore h=0 implies that the 
test has ―failed to reject null hypothesis, difference has no importance‖, and h=1 implies 
that the test ―rejects null hypothesis, difference is important‖ 
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CHAPTER 5 
Discussion and Conclusion 
In this thesis, we aimed to devise functionally important pathways for epilepsy, 
using DNA methylation levels information which was provided by a microarray based 
analysis method, Illumina HumanMethylation450 Bead Chip. The dataset was 
constructed from 10 family trios. In each family trio, the child and one of the parents are 
affected by epilepsy, and one of the parents (control parent) is not. Therefore, the 
dataset allowed us to apply a trio analysis on the data set. Two approaches that we 
developed for trio analysis were originated from the requirement to determine the 
effects of both methylated status and non-methylated status at a CpG locus, which may 
be associated to a gene and therefore may lead us to a significant pathway.  
 
At first the dataset was used without applying any filter. Although all pathway 
analysis methods which are described in this thesis were used in this stage, the results 
can’t be considered as reliable as the results of analysis with filters. Even though the 
resulting pathway lists may include significant pathways that are associated with 
epilepsy, they may also include unrelated results, because a fraction of the CpG locus 
may yield biased DNA methylation level results according to sex. Moreover, a number 
of positions in the dataset yields DNA methylation level results from non-CpG 
methylation, or SNPs directly. Pathway results that are associated with those positions 
may compromise our assessment.  
 
Along with application of two filters which were previously described in section 
3.3 in this thesis, also additional analysis on promoter-associated CpGs were separately 
done and both filters were applied in promoter analysis. Pathway results for each family 
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trio by different analysis methods (i.e., DAVID, PANOGA) were presented in the 
previous chapter. Moreover, the list of all devised pathways by DAVID is presented in 
APPENDIX B. The numbers of occurrences of pathways in different family trio 
analyses were also provided in there. Those lists were used to compare our results with 
another study by Bakir-Gungor (2013), which aims to identify epilepsy-related 
pathways. In Table 5.1, the results of Bakir-Gungor are compared with the results we 
found in this thesis. They presented top 29 KEGG pathways, therefore we used KEGG 
results from DAVID and KEGG results from PANOGA for comparison. Matching 
pathways are marked in the table.  
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KEGG pathways  a b c d e f g h 
Complement and coagulation cascades 
      
x x 
Cell cycle 
  
x x x x x x 
Focal Adhesion 
  
x 
 
x x  x 
ECM—receptor interaction 
      
  
Jak-STAT signaling pathway 
  
x x 
  
  
MAPK signaling pathway 
  
x x 
  
x  
Proteasome 
  
x 
 
x 
 
 x 
Ribosome 
    
x 
 
x x 
Calcium signaling pathway x x x x 
  
  
Regulation of actin cytoskeleton 
  
x 
   
x  
Adherens junction 
  
x x 
  
  
Pathways in cancer 
  
x x x x x x 
Gap junction 
  
x 
   
  
Apoptosis 
      
x  
Long-term depression 
  
x 
   
  
Axon guidance 
  
x x 
  
  
Fc gamma R-mediated phagocytosis 
  
x x 
  
  
Tight junction x x x x 
  
  
ErbB signaling pathway 
  
x 
   
x x 
Wnt signaling pathway 
  
x x 
  
  
Chemokine signaling pathway 
  
x x x 
 
  
GnRH signaling pathway 
      
  
Pentose phosphate pathway 
      
  
Long-term potentiation 
      
  
Neurotrophin signaling pathway 
    
x x x x 
Glycolysis/Gluconeogenesis 
      
  
Notch signaling pathway 
  
x 
   
  
Dilated cardiomyopathy 
  
x x 
  
  
TGF-beta signaling pathway 
  
x x 
  
x  
Table 5.1 Comparison of top 29 KEGG pathways by Bakir-Gungor (2013) and findings 
of this thesis. a) Promoter analysis results with first filter from DAVID (17 pathways), 
b) Promoter analysis results with second filter from DAVID (5 pathways), c) General 
analysis results with first filter from DAVID (82 pathways), d) General analysis results 
with first second filter from DAVID (54 pathways), e) Promoter analysis results with 
first filter from PANOGA (10 pathways), f) Promoter analysis results with second filter 
from PANOGA (10 pathways), g) General analysis results with first filter from 
PANOGA (20 pathways), h) General analysis results with second filter from PANOGA 
(18 pathways). 
 
General analysis with both filters show correspondence with the study (Bakir-
Gungor et al., 2013), 20 out of 29 matching pathways were identified with the first filter 
and 13 out of 29 matching pathways were identified with the second filter. Since the 
second filter also contains the first filter, the decrease in the number of identified 
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pathways for the second filter is an expected outcome.  Even though the promoter 
analysis results from DAVID do not show correspondence with the study (only 2 out of 
29 pathways were identified), it is also an expected outcome, because the pathway lists 
for promoter analysis with DAVID contains relatively small number of pathways. The 
list with the first filter contains 17 pathways and the list with the second filter contains 
only 5 pathways. On the other hand, containing a number of 10 pathways, combined 
results (combination of the results of first and second approaches) of promoter analysis 
from PANOGA shows better results by identifying 7 (first filter) and 4 (second filter) 
matching pathways. Moreover, combined results of general analysis from PANOGA 
also provide better outcomes than DAVID by identifying 10 out of 20 pathways (first 
filter) and 8 out of 18 pathways (second filter).  
 
Comparison of the results by Bakir-Gungor and PANOGA results of the analysis 
with third approach are presented in Table 5.2.  
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KEGG Pathways a b c d e 
Complement and coagulation cascades     x x x 
Cell cycle   x x x x 
Focal Adhesion           
ECM—receptor interaction           
Jak-STAT signaling pathway           
MAPK signaling pathway           
Proteasome     x     
Ribosome x x x x x 
Calcium signaling pathway           
Regulation of actin cytoskeleton           
Adherens junction       x x 
Pathways in cancer x     x x 
Gap junction           
Apoptosis x         
Long-term depression           
Axon guidance           
Fc gamma R-mediated phagocytosis           
Tight junction           
ErbB signaling pathway           
Wnt signaling pathway           
Chemokine signaling pathway   x x x x 
GnRH signaling pathway           
Pentose phosphate pathway           
Long-term potentiation   x       
Neurotrophin signaling pathway x     x x 
Glycolysis/Gluconeogenesis           
Notch signaling pathway           
Dilated cardiomyopathy           
TGF-beta signaling pathway   x x     
Table 5.2 Comparison of top 29 KEGG pathways by Bakir-Gungor (2013) and findings 
of this thesis. a) Third approach results without filter from PANOGA (10 pathways), b) 
Third approach results of general analysis with first filter from PANOGA (10 
pathways), c) Third approach results of general analysis with second filter from 
PANOGA (10 pathways), d) Third approach results of promoter analysis with first filter 
from PANOGA (10 pathways), e) Third approach results of promoter analysis with 
second filter from PANOGA (10 pathways) 
 
Third approach results from PANOGA shows significant correspondence with 
the findings of Bakir-Gungor. Since the results of the analysis without any filters 
contains only 3 pathways out of 10, it can be concluded that filtered analysis from 
PANOGA provides better results. General analysis results contain 5 matching pathways 
with first filter and 6 matching pathways with second filter. Promoter analysis results 
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shows better correspondence with the findings off Bakir-Gungor and contains 7 
matching pathways for both filters.  
 
Comparison of the results of Bakir-Gungor and the third approach results with 
normalization from PANOGA are presented in Table 5.3. 
 
KEGG Pathways a b c d 
Complement and coagulation cascades x x x x 
Cell cycle x 
 
x 
 Focal Adhesion x 
   ECM—receptor interaction 
 
x 
  Jak-STAT signaling pathway 
    MAPK signaling pathway 
    Proteasome 
 
x 
 
x 
Ribosome x x x 
 Calcium signaling pathway 
    Regulation of actin cytoskeleton 
    Adherens junction 
    Pathways in cancer x 
 
x 
 Gap junction 
    Apoptosis 
    Long-term depression 
    Axon guidance 
    Fc gamma R-mediated phagocytosis 
    Tight junction 
    ErbB signaling pathway x 
   Wnt signaling pathway 
    Chemokine signaling pathway 
    GnRH signaling pathway 
    Pentose phosphate pathway 
    Long-term potentiation 
    Neurotrophin signaling pathway x 
 
x 
 Glycolysis/Gluconeogenesis 
    Notch signaling pathway 
 
x 
 
x 
Dilated cardiomyopathy 
    TGF-beta signaling pathway x x 
  
Table 5.3 Comparison of top 29 KEGG pathways by Bakir-Gungor (2013) and findings 
of this thesis. a) General analysis normalization results with first filter (10 pathways), b) 
General analysis normalization results with second filter (10 pathways), c) Promoter 
analysis normalization results with first filter (10 pathways), d) Promoter analysis 
normalization results with second filter (10 pathways) 
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General analysis results with normalization shows a significant correspondence 
with results of Bakir-Gungor by matching 8 pathways with first filter and 7 pathways 
with second filter. On the other hand, promoter analysis results with normalization 
shows less correspondence by matching 5 pathways with first filter and only three 
pathways with second filter. Even though promoter analysis with normalization seems 
to perform worse, showing less correspondence with previous findings may also 
indicate the possibility of newly found epilepsy-related pathways in the results of this 
thesis.  
 
Comparison of the results of Bakir-Gungor and quality checking results with 
third approach are presented in Table 5.4.  
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KEGG Pathways a b 
Complement and coagulation cascades 
  Cell cycle 
  Focal Adhesion 
 
x 
ECM—receptor interaction 
  Jak-STAT signaling pathway 
  MAPK signaling pathway 
  Proteasome x 
 Ribosome x 
 Calcium signaling pathway 
  Regulation of actin cytoskeleton 
  Adherens junction 
 
x 
Pathways in cancer 
 
x 
Gap junction 
  Apoptosis 
  Long-term depression 
  Axon guidance 
  Fc gamma R-mediated phagocytosis 
  Tight junction 
  ErbB signaling pathway 
 
x 
Wnt signaling pathway 
  Chemokine signaling pathway 
  GnRH signaling pathway 
  Pentose phosphate pathway 
  Long-term potentiation 
  Neurotrophin signaling pathway 
 
x 
Glycolysis/Gluconeogenesis 
  Notch signaling pathway 
  Dilated cardiomyopathy 
  TGF-beta signaling pathway 
  
Table 5.4 Comparison of top 29 KEGG pathways by Bakir-Gungor (2013) and findings 
of this thesis. a) Quality checking without normalization results with second filter 
(general analysis), b) Quality checking with normalization results with second filter 
(general analysis) 
 
Even though quality checking with normalization results shows moderate 
correspondence with the results of Bakir-Gungor, quality checking without 
normalization results shows less correlation. This may be resulted from the fact that 
family trio 7, which was removed in the process of quality checking, provides a high 
number of marked genes when compared to other family trios. Moreover, promoter 
analysis did not yield any results without normalization, and it only provides one 
pathway with normalization, and a possible reason behind this being the removal of 
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family trio 7 is highly likely. On the other hand, results of the quality checking includes 
some pathways that did not appear on the lists of previous studies and other analysis 
results of this thesis, but they may also indicate the possibility of newly found epilepsy-
related pathways. 
 
Other than those uniquely found pathways, the existence of many immune 
system related pathways is a remarkable outcome. This novel found may contribute to 
explain the relationship between immune system and epileptogenesis. 
 
In this thesis, common motifs around methylated and unmethylated nucleotide 
sequences were also found. Since the sequence information of methylation data used in 
this thesis wasn’t provided yet, MethDB database were used in this process. When the 
sequence information of methylation data is acquired, same analysis can be repeated to 
compare the common motifs found, and those common motifs can be searched around 
the marked CpG islands which are differentially methylated in family trios. If a 
common motif is found around a certain CpG island in a sample, and doesn’t appear 
around the same CpG Island in other family members, this situation may lead to find a 
relationship between the mutations of certain motifs around a CpG island and 
methylation level of it. 
 
The statistical analysis shows that there is a significant difference between DNA 
methylation levels affected samples and control samples. 29 out of 33 Wilcoxon rank-
sum test results and 26 out of 33 Student’s t-test results imply this conclusion. The work 
of this thesis can be continued by determining specific regions in the genome which are 
differentially methylated. Associated pathways can be identified by related genes in 
those differentially methylated regions. A comparison between trio analysis results and 
results from the new analysis may provide further validation for identified pathways.  
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APPENDIX A  
 
Results without Filtering 
 
 Ap denotes the approach used in the analysis and F denotes the number of the 
family.  
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Method Ap Pathway F Data 
DAVID 1st KEGG 1 hsa04070:Phosphatidylinositol signaling system 
DAVID 1st KEGG 1 hsa00562:Inositol phosphate metabolism 
DAVID 1st KEGG 6 hsa04940:Type I diabetes mellitus 
DAVID 1st KEGG 6 hsa05330:Allograft rejection 
DAVID 1st KEGG 6 hsa05332:Graft-versus-host disease 
DAVID 1st KEGG 6 hsa05320:Autoimmune thyroid disease 
DAVID 1st KEGG 6 hsa05416:Viral myocarditis 
DAVID 1st KEGG 6 hsa04612:Antigen processing and presentation 
DAVID 1st KEGG 6 hsa04514:Cell adhesion molecules (CAMs) 
DAVID 1st KEGG 6 hsa05310:Asthma 
DAVID 1st KEGG 6 
hsa04672:Intestinal immune network for IgA 
production 
DAVID 1st KEGG 7 hsa04310:Wnt signaling pathway 
DAVID 1st KEGG 7 hsa00100:Steroid biosynthesis 
DAVID 1st KEGG 7 hsa05200:Pathways in cancer 
DAVID 1st KEGG 9 hsa04514:Cell adhesion molecules (CAMs) 
DAVID 2nd KEGG 7 hsa04144:Endocytosis 
DAVID 2nd KEGG 7 hsa04062:Chemokine signaling pathway 
DAVID 2nd KEGG 7 hsa04110:Cell cycle 
DAVID 2nd KEGG 8 hsa05330:Allograft rejection 
DAVID 2nd KEGG 8 hsa05332:Graft-versus-host disease 
DAVID 2nd KEGG 8 hsa04940:Type I diabetes mellitus  
DAVID 2nd KEGG 8 hsa05320:Autoimmune thyroid disease 
DAVID 1st BioCarta 7 h_p38mapkPathway:p38 MAPK Signaling Pathway  
DAVID 1st Panther 7 P00057:Wnt signaling pathway 
DAVID 1st Panther 3 P00047:PDGF signaling pathway 
DAVID 1st Panther 3 
P00041:Metabotropic glutamate receptor group I 
pathway 
DAVID 1st Panther 3 P00019:Endothelin signaling pathway 
DAVID 2nd Panther 7 
P00026:Heterotrimeric G-protein signaling 
pathway-Gi alpha and Gs alpha mediated pathway 
DAVID 2nd Panther 7 
P00027:Heterotrimeric G-protein signaling 
pathway-Gq alpha and Go alpha mediated pathway 
DAVID 2nd Panther 7 P00052:TGF-beta signaling pathway 
DAVID 1st Reactome 3 
REACT_9480:Gap junction trafficking and 
regulation 
DAVID 1st Reactome 9 REACT_604:Hemostasis 
GOrilla 1st - 3 GO:0009605:response to external stimulus 
GOrilla 1st - 7 GO:0002253:activation of immune response 
GOrilla 1st - 7 
GO:0002429:immune response-activating cell 
surface receptor signaling pathway 
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GOrilla 1st - 7 
GO:0002757:immune response-activating signal 
transduction 
GOrilla 1st - 7 
GO:0002768:immune response-regulating cell 
surface receptor signaling pathway 
GOrilla 1st - 7 
GO:0002764:immune response-regulating signaling 
pathway 
GOrilla 1st - 7 
GO:0002696:positive regulation of leukocyte 
activation 
GOrilla 1st - 7 
GO:0050778:positive regulation of immune 
response 
GOrilla 1st - 7 GO:0050870:positive regulation of T cell activation 
GOrilla 1st - 7 GO:0050852:T cell receptor signaling pathway 
GOrilla 1st - 7 
GO:0050851:antigen receptor-mediated signaling 
pathway 
GOrilla 1st - 7 GO:0050863:regulation of T cell activation 
GOrilla 1st - 7 GO:0050867:positive regulation of cell activation 
GOrilla 1st - 7 
GO:0051251:positive regulation of lymphocyte 
activation 
GOrilla 1st - 7 GO:0051249:regulation of lymphocyte activation 
PANOGA 1st KEGG 1 Metabolic pathways 
PANOGA 1st KEGG 1 Pathways in cancer 
PANOGA 1st KEGG 1 Neurotrophin signaling pathway 
PANOGA 1st KEGG 1 Focal adhesion 
PANOGA 1st KEGG 1 Cell cycle 
PANOGA 1st KEGG 1 HTLV-I infection 
PANOGA 1st KEGG 1 Small cell lung cancer 
PANOGA 1st KEGG 1 Ribosome 
PANOGA 1st KEGG 1 ErbB signaling pathway 
PANOGA 1st KEGG 1 MAPK signaling pathway 
PANOGA 2nd KEGG 2 Metabolic pathways 
PANOGA 2nd KEGG 2 Pathways in cancer 
PANOGA 2nd KEGG 2 Cell cycle 
PANOGA 2nd KEGG 2 Neurotrophin signaling pathway 
PANOGA 2nd KEGG 2 Focal adhesion 
PANOGA 2nd KEGG 2 HTLV-I infection 
PANOGA 2nd KEGG 2 Prostate cancer 
PANOGA 2nd KEGG 2 Small cell lung cancer 
PANOGA 2nd KEGG 2 Chronic myeloid leukemia 
PANOGA 2nd KEGG 2 Pancreatic cancer 
PANOGA 1st KEGG 5 ErbB signaling pathway 
PANOGA 1st KEGG 5 Adherens junction 
PANOGA 1st KEGG 5 Bacterial invasion of epithelial cells 
PANOGA 1st KEGG 5 Dorso-ventral axis formation 
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PANOGA 1st KEGG 5 Thyroid cancer 
PANOGA 2nd KEGG 5 Non-homologous end-joining 
PANOGA 1st KEGG 6 Focal adhesion 
PANOGA 1st KEGG 6 Pathways in cancer 
PANOGA 1st KEGG 6 Ribosome 
PANOGA 1st KEGG 6 Regulation of actin cytoskeleton 
PANOGA 1st KEGG 6 Chemokine signaling pathway 
PANOGA 1st KEGG 6 ErbB signaling pathway 
PANOGA 1st KEGG 6 Cell cycle 
PANOGA 1st KEGG 6 Nucleotide excision repair 
PANOGA 1st KEGG 6 Metabolic pathways 
PANOGA 1st KEGG 6 Neurotrophin signaling pathway 
PANOGA 1st KEGG 7 Chronic myeloid leukemia 
PANOGA 1st KEGG 7 Long-term potentiation 
PANOGA 1st KEGG 7 NOD-like receptor signaling pathway 
PANOGA 1st KEGG 7 Proteasome 
PANOGA 1st KEGG 7 Acute myeloid leukemia 
PANOGA 1st KEGG 7 Thyroid cancer 
PANOGA 1st KEGG 7 Prion diseases 
PANOGA 2nd KEGG 8 Glyoxylate and dicarboxylate metabolism 
PANOGA 1st KEGG 9 RNA polymerase 
PANOGA 1st KEGG 9 Cytosolic DNA-sensing pathway 
PANOGA 1st KEGG 9 Prion diseases 
PANOGA 1st KEGG 10 Colorectal cancer 
PANOGA 1st KEGG 10 Non-homologous end-joining 
PANOGA 1st KEGG 10 Thyroid cancer 
PANOGA 2nd KEGG 10 Citrate cycle (TCA cycle) 
PANOGA 2nd KEGG 10 Valine 
PANOGA 2nd KEGG 10 Glyoxylate and dicarboxylate metabolism 
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APPENDIX B  
 
Results with Filtering 
 
 Fi denotes the number of the filter used in the analysis, P shows whether the 
analysis is based on promoter regions or not (i.e. 1 means it is based on promoter 
regions, 0 means it is not) and finally F shows number of the family.  
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Fi P Ap Pathway F Data 
1st 0 1st BioCarta 1 h_rhodopsinPathway:Visual Signal Transduction 
1st 0 1st BioCarta 2 
h_asbcellPathway:Antigen Dependent B Cell 
Activation 
1st 0 1st BioCarta 2 h_bbcellPathway:Bystander B Cell Activation 
1st 0 1st BioCarta 2 
h_blymphocytePathway:B Lymphocyte Cell Surface 
Molecules 
1st 0 1st BioCarta 2 
h_CSKPathway:Activation of Csk by cAMP-
dependent Protein Kinase Inhibits Signaling through 
the T Cell Receptor 
1st 0 1st BioCarta 2 
h_ctla4Pathway:The Co-Stimulatory Signal During 
T-cell Activation 
1st 0 1st BioCarta 2 
h_eosinophilsPathway:The Role of Eosinophils in 
the Chemokine Network of Allergy 
1st 0 1st BioCarta 2 h_il5Pathway:IL 5 Signaling Pathway 
1st 0 1st BioCarta 2 
h_inflamPathway:Cytokines and Inflammatory 
Response 
1st 0 1st BioCarta 2 
h_metPathway:Signaling of Hepatocyte Growth 
Factor Receptor 
1st 0 1st BioCarta 2 h_mhcPathway:Antigen Processing and Presentation 
1st 0 1st BioCarta 2 
h_tcraPathway:Lck and Fyn tyrosine kinases in 
initiation of TCR Activation 
1st 0 1st BioCarta 2 h_th1th2Pathway:Th1/Th2 Differentiation 
1st 0 1st BioCarta 3 h_actinYPathway:Y branching of actin filaments 
1st 0 1st BioCarta 3 h_alkPathway:ALK in cardiac myocytes 
1st 0 1st BioCarta 3 
h_asbcellPathway:Antigen Dependent B Cell 
Activation 
1st 0 1st BioCarta 3 h_bbcellPathway:Bystander B Cell Activation 
1st 0 1st BioCarta 3 
h_blymphocytePathway:B Lymphocyte Cell Surface 
Molecules 
1st 0 1st BioCarta 3 
h_CSKPathway:Activation of Csk by cAMP-
dependent Protein Kinase Inhibits Signaling through 
the T Cell Receptor 
1st 0 1st BioCarta 3 
h_ctcfPathway:CTCF: First Multivalent Nuclear 
Factor 
1st 0 1st BioCarta 3 
h_ctla4Pathway:The Co-Stimulatory Signal During 
T-cell Activation 
1st 0 1st BioCarta 3 
h_eosinophilsPathway:The Role of Eosinophils in 
the Chemokine Network of Allergy 
1st 0 1st BioCarta 3 h_il5Pathway:IL 5 Signaling Pathway 
1st 0 1st BioCarta 3 
h_inflamPathway:Cytokines and Inflammatory 
Response 
1st 0 1st BioCarta 3 h_mhcPathway:Antigen Processing and Presentation 
1st 0 1st BioCarta 3 
h_tcraPathway:Lck and Fyn tyrosine kinases in 
initiation of TCR Activation 
1st 0 1st BioCarta 3 h_th1th2Pathway:Th1/Th2 Differentiation 
1st 0 1st BioCarta 3 h_tob1Pathway:Role of Tob in T-cell activation 
1st 0 1st BioCarta 5 h_integrinPathway:Integrin Signaling Pathway 
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1st 0 1st BioCarta 5 
h_metPathway:Signaling of Hepatocyte Growth 
Factor Receptor 
1st 0 1st BioCarta 6 
h_asbcellPathway:Antigen Dependent B Cell 
Activation 
1st 0 1st BioCarta 6 h_bbcellPathway:Bystander B Cell Activation 
1st 0 1st BioCarta 6 
h_blymphocytePathway:B Lymphocyte Cell Surface 
Molecules 
1st 0 1st BioCarta 6 
h_CSKPathway:Activation of Csk by cAMP-
dependent Protein Kinase Inhibits Signaling through 
the T Cell Receptor 
1st 0 1st BioCarta 6 
h_ctla4Pathway:The Co-Stimulatory Signal During 
T-cell Activation 
1st 0 1st BioCarta 6 
h_eosinophilsPathway:The Role of Eosinophils in 
the Chemokine Network of Allergy 
1st 0 1st BioCarta 6 h_il5Pathway:IL 5 Signaling Pathway 
1st 0 1st BioCarta 6 
h_inflamPathway:Cytokines and Inflammatory 
Response 
1st 0 1st BioCarta 6 h_integrinPathway:Integrin Signaling Pathway 
1st 0 1st BioCarta 6 
h_longevityPathway:The IGF-1 Receptor and 
Longevity 
1st 0 1st BioCarta 6 h_mhcPathway:Antigen Processing and Presentation 
1st 0 1st BioCarta 6 
h_tcraPathway:Lck and Fyn tyrosine kinases in 
initiation of TCR Activation 
1st 0 1st BioCarta 6 h_th1th2Pathway:Th1/Th2 Differentiation 
1st 0 1st BioCarta 8 
h_reckPathway:Inhibition of Matrix 
Metalloproteinases 
1st 0 1st BioCarta 9 h_agpcrPathway:Attenuation of GPCR Signaling 
1st 0 1st BioCarta 9 
h_arenrf2Pathway:Oxidative Stress Induced Gene 
Expression Via Nrf2 
1st 0 1st BioCarta 9 
h_At1rPathway:Angiotensin II mediated activation 
of JNK Pathway via Pyk2 dependent signaling 
1st 0 1st BioCarta 9 h_bcrPathway:BCR Signaling Pathway 
1st 0 1st BioCarta 9 
h_biopeptidesPathway:Bioactive Peptide Induced 
Signaling Pathway 
1st 0 1st BioCarta 9 
h_calcineurinPathway:Effects of calcineurin in 
Keratinocyte Differentiation 
1st 0 1st BioCarta 9 
h_cardiacegfPathway:Role of EGF Receptor 
Transactivation by GPCRs in Cardiac Hypertrophy 
1st 0 1st BioCarta 9 
h_cblPathway:CBL mediated ligand-induced 
downregulation of EGF receptors 
1st 0 1st BioCarta 9 h_CCR3Pathway:CCR3 signaling in Eosinophils 
1st 0 1st BioCarta 9 
h_Ccr5Pathway:Pertussis toxin-insensitive CCR5 
Signaling in Macrophage 
1st 0 1st BioCarta 9 
h_cdMacPathway:Cadmium induces DNA synthesis 
and proliferation in macrophages 
1st 0 1st BioCarta 9 
h_chemicalPathway:Apoptotic Signaling in 
Response to DNA Damage 
1st 0 1st BioCarta 9 h_cxcr4Pathway:CXCR4 Signaling Pathway 
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1st 0 1st BioCarta 9 
h_edg1Pathway:Phospholipids as signalling 
intermediaries 
1st 0 1st BioCarta 9 h_egfPathway:EGF Signaling Pathway 
1st 0 1st BioCarta 9 
h_eif4Pathway:Regulation of eIF4e and p70 S6 
Kinase 
1st 0 1st BioCarta 9 
h_erbB4pathway:g-Secretase mediated ErbB4 
Signaling Pathway 
1st 0 1st BioCarta 9 h_ghPathway:Growth Hormone Signaling Pathway 
1st 0 1st BioCarta 9 
h_gpcrPathway:Signaling Pathway from G-Protein 
Families 
1st 0 1st BioCarta 9 
h_ionPathway:Ion Channel and Phorbal Esters 
Signaling Pathway 
1st 0 1st BioCarta 9 h_keratinocytePathway:Keratinocyte Differentiation 
1st 0 1st BioCarta 9 
h_mef2dPathway:Role of MEF2D in T-cell 
Apoptosis 
1st 0 1st BioCarta 9 
h_myosinPathway:PKC-catalyzed phosphorylation 
of inhibitory phosphoprotein of myosin phosphatase 
1st 0 1st BioCarta 9 h_nos1Pathway:Nitric Oxide Signaling Pathway 
1st 0 1st BioCarta 9 
h_Par1Pathway:Thrombin signaling and protease-
activated receptors 
1st 0 1st BioCarta 9 h_pdgfPathway:PDGF Signaling Pathway 
1st 0 1st BioCarta 9 
h_pkcPathway:Activation of PKC through G protein 
coupled receptor 
1st 0 1st BioCarta 9 
h_plcdPathway:Phospholipase C d1 in phospholipid 
associated cell signaling 
1st 0 1st BioCarta 9 h_plcPathway:Phospholipase C Signaling Pathway 
1st 0 1st BioCarta 9 
h_pparaPathway:Mechanism of Gene Regulation by 
Peroxisome Proliferators via PPARa(alpha) 
1st 0 1st BioCarta 9 
h_pyk2Pathway:Links between Pyk2 and Map 
Kinases 
1st 0 1st BioCarta 9 
h_sppaPathway:Aspirin Blocks Signaling Pathway 
Involved in Platelet Activation 
1st 0 1st BioCarta 9 
h_srcRPTPPathway:Activation of Src by Protein-
tyrosine phosphatase alpha 
1st 0 1st BioCarta 9 h_tcrPathway:T Cell Receptor Signaling Pathway 
1st 0 1st BioCarta 9 
h_telPathway:Telomeres, Telomerase, Cellular 
Aging, and  Immortality,h_TPOPathway:TPO 
Signaling Pathway 
1st 0 1st BioCarta 9 h_trkaPathway:Trka Receptor Signaling Pathway 
1st 0 1st BioCarta 9 h_vegfPathway:VEGF, Hypoxia, and Angiogenesis 
2nd 0 1st BioCarta 2 
h_asbcellPathway:Antigen Dependent B Cell 
Activation 
2nd 0 1st BioCarta 2 h_bbcellPathway:Bystander B Cell Activation 
2nd 0 1st BioCarta 2 
h_blymphocytePathway:B Lymphocyte Cell Surface 
Molecules 
2nd 0 1st BioCarta 2 
h_CSKPathway:Activation of Csk by cAMP-
dependent Protein Kinase Inhibits Signaling through 
the T Cell Receptor 
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2nd 0 1st BioCarta 2 
h_ctla4Pathway:The Co-Stimulatory Signal During 
T-cell Activation 
2nd 0 1st BioCarta 2 
h_eosinophilsPathway:The Role of Eosinophils in 
the Chemokine Network of Allergy 
2nd 0 1st BioCarta 2 
h_il5Pathway:IL 5 Signaling 
Pathway,h_inflamPathway:Cytokines and 
Inflammatory Response 
2nd 0 1st BioCarta 2 h_mhcPathway:Antigen Processing and Presentation 
2nd 0 1st BioCarta 2 
h_tcraPathway:Lck and Fyn tyrosine kinases in 
initiation of TCR Activation 
2nd 0 1st BioCarta 2 h_th1th2Pathway:Th1/Th2 Differentiation 
2nd 0 1st BioCarta 3 
h_asbcellPathway:Antigen Dependent B Cell 
Activation 
2nd 0 1st BioCarta 3 h_bbcellPathway:Bystander B Cell Activation 
2nd 0 1st BioCarta 3 
h_blymphocytePathway:B Lymphocyte Cell Surface 
Molecules 
2nd 0 1st BioCarta 3 
h_CSKPathway:Activation of Csk by cAMP-
dependent Protein Kinase Inhibits Signaling through 
the T Cell Receptor 
2nd 0 1st BioCarta 3 
h_ctla4Pathway:The Co-Stimulatory Signal During 
T-cell Activation 
2nd 0 1st BioCarta 3 
h_eosinophilsPathway:The Role of Eosinophils in 
the Chemokine Network of Allergy 
2nd 0 1st BioCarta 3 h_il5Pathway:IL 5 Signaling Pathway 
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2nd 0 1st KEGG 2 hsa04514:Cell adhesion molecules (CAMs) 
2nd 0 1st KEGG 2 hsa04612:Antigen processing and presentation 
2nd 0 1st KEGG 2 hsa04640:Hematopoietic cell lineage 
2nd 0 1st KEGG 2 
hsa04672:Intestinal immune network for IgA 
production 
2nd 0 1st KEGG 2 hsa04940:Type I diabetes mellitus 
2nd 0 1st KEGG 2 hsa05310:Asthma 
2nd 0 1st KEGG 2 hsa05320:Autoimmune thyroid disease 
2nd 0 1st KEGG 2 hsa05322:Systemic lupus erythematosus 
2nd 0 1st KEGG 2 hsa05330:Allograft rejection 
2nd 0 1st KEGG 2 hsa05332:Graft-versus-host disease 
2nd 0 1st KEGG 2 hsa05416:Viral myocarditis 
2nd 0 1st KEGG 3 hsa04514:Cell adhesion molecules (CAMs) 
2nd 0 1st KEGG 3 hsa04612:Antigen processing and presentation 
2nd 0 1st KEGG 3 hsa04640:Hematopoietic cell lineage 
2nd 0 1st KEGG 3 
hsa04672:Intestinal immune network for IgA 
production 
2nd 0 1st KEGG 3 hsa04940:Type I diabetes mellitus 
2nd 0 1st KEGG 3 hsa05310:Asthma 
2nd 0 1st KEGG 3 hsa05320:Autoimmune thyroid disease 
2nd 0 1st KEGG 3 hsa05322:Systemic lupus erythematosus 
2nd 0 1st KEGG 3 hsa05330:Allograft rejection 
2nd 0 1st KEGG 3 hsa05332:Graft-versus-host disease 
2nd 0 1st KEGG 3 hsa05416:Viral myocarditis 
2nd 0 1st KEGG 4 hsa04530:Tight junction 
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2nd 0 1st KEGG 5 hsa04530:Tight junction 
2nd 0 1st KEGG 6 hsa04514:Cell adhesion molecules (CAMs) 
2nd 0 1st KEGG 6 hsa04612:Antigen processing and presentation 
2nd 0 1st KEGG 6 
hsa04672:Intestinal immune network for IgA 
production 
2nd 0 1st KEGG 6 hsa04940:Type I diabetes mellitus 
2nd 0 1st KEGG 6 hsa05310:Asthma 
2nd 0 1st KEGG 6 hsa05320:Autoimmune thyroid disease 
2nd 0 1st KEGG 6 hsa05322:Systemic lupus erythematosus 
2nd 0 1st KEGG 6 hsa05330:Allograft rejection 
2nd 0 1st KEGG 6 hsa05332:Graft-versus-host disease 
2nd 0 1st KEGG 6 hsa05416:Viral myocarditis 
2nd 0 1st KEGG 7 hsa03040:Spliceosome 
2nd 0 1st KEGG 7 hsa04020:Calcium signaling pathway 
2nd 0 1st KEGG 7 hsa04080:Neuroactive ligand-receptor interaction 
2nd 0 1st KEGG 7 hsa04310:Wnt signaling pathway 
2nd 0 1st KEGG 7 hsa04520:Adherens junction 
2nd 0 1st KEGG 7 hsa04916:Melanogenesis 
2nd 0 1st KEGG 7 hsa05200:Pathways in cancer 
2nd 0 1st KEGG 7 hsa05210:Colorectal cancer 
2nd 0 1st KEGG 7 hsa05211:Renal cell carcinoma 
2nd 0 1st KEGG 7 hsa05213:Endometrial cancer 
2nd 0 1st KEGG 7 hsa05215:Prostate cancer 
2nd 0 1st KEGG 7 hsa05216:Thyroid cancer 
2nd 0 1st KEGG 7 hsa05217:Basal cell carcinoma 
2nd 0 1st KEGG 7 hsa05221:Acute myeloid leukemia 
2nd 0 1st KEGG 7 
hsa05412:Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
2nd 0 1st KEGG 10 hsa04340:Hedgehog signaling pathway 
2nd 0 1st KEGG 10 hsa04740:Olfactory transduction 
1st 1 1st KEGG 3 hsa04514:Cell adhesion molecules (CAMs) 
1st 1 1st KEGG 3 hsa04612:Antigen processing and presentation 
1st 1 1st KEGG 3 hsa04640:Hematopoietic cell lineage 
1st 1 1st KEGG 3 
hsa04672:Intestinal immune network for IgA 
production 
1st 1 1st KEGG 3 hsa04940:Type I diabetes mellitus 
1st 1 1st KEGG 3 hsa05310:Asthma 
1st 1 1st KEGG 3 hsa05320:Autoimmune thyroid disease 
1st 1 1st KEGG 3 hsa05322:Systemic lupus erythematosus 
1st 1 1st KEGG 3 hsa05330:Allograft rejection 
1st 1 1st KEGG 3 hsa05332:Graft-versus-host disease 
1st 1 1st KEGG 3 hsa05416:Viral myocarditis 
1st 1 1st KEGG 4 hsa04530:Tight junction 
1st 1 1st KEGG 6 hsa04080:Neuroactive ligand-receptor interaction 
1st 1 1st KEGG 7 hsa04020:Calcium signaling pathway 
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1st 1 1st KEGG 7 hsa04080:Neuroactive ligand-receptor interaction 
1st 1 1st KEGG 7 hsa04514:Cell adhesion molecules (CAMs) 
1st 1 1st KEGG 7 hsa04612:Antigen processing and presentation 
1st 1 1st KEGG 7 
hsa04672:Intestinal immune network for IgA 
production 
1st 1 1st KEGG 7 hsa04940:Type I diabetes mellitus 
1st 1 1st KEGG 7 hsa05310:Asthma 
1st 1 1st KEGG 7 hsa05320:Autoimmune thyroid disease 
1st 1 1st KEGG 7 hsa05322:Systemic lupus erythematosus 
1st 1 1st KEGG 7 hsa05330:Allograft rejection 
1st 1 1st KEGG 7 hsa05332:Graft-versus-host disease 
1st 1 1st KEGG 7 hsa05416:Viral myocarditis 
1st 1 1st KEGG 8 hsa02010:ABC transporters 
1st 1 1st KEGG 10 hsa04740:Olfactory transduction 
2nd 1 1st KEGG 4 hsa04530:Tight junction 
2nd 1 1st KEGG 7 hsa04020:Calcium signaling pathway 
2nd 1 1st KEGG 7 hsa04080:Neuroactive ligand-receptor interaction 
2nd 1 1st KEGG 10 hsa04740:Olfactory transduction 
1st 0 2nd KEGG 1 hsa04740:Olfactory transduction 
1st 0 2nd KEGG 3 hsa04010:MAPK signaling pathway 
1st 0 2nd KEGG 3 hsa04012:ErbB signaling pathway 
1st 0 2nd KEGG 3 hsa04020:Calcium signaling pathway 
1st 0 2nd KEGG 3 hsa04070:Phosphatidylinositol signaling system 
1st 0 2nd KEGG 3 hsa04270:Vascular smooth muscle contraction 
1st 0 2nd KEGG 3 hsa04310:Wnt signaling pathway 
1st 0 2nd KEGG 3 hsa04370:VEGF signaling pathway 
1st 0 2nd KEGG 3 hsa04510:Focal adhesion 
1st 0 2nd KEGG 3 hsa04514:Cell adhesion molecules (CAMs) 
1st 0 2nd KEGG 3 hsa04530:Tight junction 
1st 0 2nd KEGG 3 hsa04540:Gap junction 
1st 0 2nd KEGG 3 hsa04612:Antigen processing and presentation 
1st 0 2nd KEGG 3 hsa04640:Hematopoietic cell lineage 
1st 0 2nd KEGG 3 hsa04650:Natural killer cell mediated cytotoxicity 
1st 0 2nd KEGG 3 hsa04664:Fc epsilon RI signaling pathway 
1st 0 2nd KEGG 3 hsa04666:Fc gamma R-mediated phagocytosis 
1st 0 2nd KEGG 3 hsa04670:Leukocyte transendothelial migration 
1st 0 2nd KEGG 3 
hsa04672:Intestinal immune network for IgA 
production 
1st 0 2nd KEGG 3 hsa04720:Long-term potentiation 
1st 0 2nd KEGG 3 hsa04730:Long-term depression 
1st 0 2nd KEGG 3 hsa04912:GnRH signaling pathway 
1st 0 2nd KEGG 3 hsa04916:Melanogenesis 
1st 0 2nd KEGG 3 hsa04940:Type I diabetes mellitus 
1st 0 2nd KEGG 3 
hsa04960:Aldosterone-regulated sodium 
reabsorption 
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1st 0 2nd KEGG 3 hsa05110:Vibrio cholerae infection 
1st 0 2nd KEGG 3 hsa05130:Pathogenic Escherichia coli infection 
1st 0 2nd KEGG 3 hsa05200:Pathways in cancer 
1st 0 2nd KEGG 3 hsa05214:Glioma 
1st 0 2nd KEGG 3 hsa05223:Non-small cell lung cancer 
1st 0 2nd KEGG 3 hsa05310:Asthma 
1st 0 2nd KEGG 3 hsa05320:Autoimmune thyroid disease 
1st 0 2nd KEGG 3 hsa05322:Systemic lupus erythematosus 
1st 0 2nd KEGG 3 hsa05330:Allograft rejection 
1st 0 2nd KEGG 3 hsa05332:Graft-versus-host disease 
1st 0 2nd KEGG 3 hsa05416:Viral myocarditis 
1st 0 2nd KEGG 4 hsa04340:Hedgehog signaling pathway 
1st 0 2nd KEGG 4 hsa04740:Olfactory transduction 
1st 0 2nd KEGG 6 hsa04010:MAPK signaling pathway 
1st 0 2nd KEGG 6 hsa04012:ErbB signaling pathway 
1st 0 2nd KEGG 6 hsa04020:Calcium signaling pathway 
1st 0 2nd KEGG 6 hsa04070:Phosphatidylinositol signaling system 
1st 0 2nd KEGG 6 hsa04270:Vascular smooth muscle contraction 
1st 0 2nd KEGG 6 hsa04310:Wnt signaling pathway 
1st 0 2nd KEGG 6 hsa04370:VEGF signaling pathway 
1st 0 2nd KEGG 6 hsa04510:Focal adhesion 
1st 0 2nd KEGG 6 hsa04514:Cell adhesion molecules (CAMs) 
1st 0 2nd KEGG 6 hsa04530:Tight junction 
1st 0 2nd KEGG 6 hsa04540:Gap junction 
1st 0 2nd KEGG 6 hsa04612:Antigen processing and presentation 
1st 0 2nd KEGG 6 hsa04640:Hematopoietic cell lineage 
1st 0 2nd KEGG 6 hsa04650:Natural killer cell mediated cytotoxicity 
1st 0 2nd KEGG 6 hsa04664:Fc epsilon RI signaling pathway 
1st 0 2nd KEGG 6 hsa04666:Fc gamma R-mediated phagocytosis 
1st 0 2nd KEGG 6 hsa04670:Leukocyte transendothelial migration 
1st 0 2nd KEGG 6 
hsa04672:Intestinal immune network for IgA 
production 
1st 0 2nd KEGG 6 hsa04720:Long-term potentiation 
1st 0 2nd KEGG 6 hsa04730:Long-term depression 
1st 0 2nd KEGG 6 hsa04912:GnRH signaling pathway 
1st 0 2nd KEGG 6 hsa04916:Melanogenesis 
1st 0 2nd KEGG 6 hsa04940:Type I diabetes mellitus 
1st 0 2nd KEGG 6 hsa04960:Aldosterone-regulated sodiumreabsorption 
1st 0 2nd KEGG 6 hsa05110:Vibrio cholerae infection 
1st 0 2nd KEGG 6 hsa05130:Pathogenic Escherichia coli infection 
1st 0 2nd KEGG 6 hsa05200:Pathways in cancer 
1st 0 2nd KEGG 6 hsa05214:Glioma 
1st 0 2nd KEGG 6 hsa05223:Non-small cell lung cancer 
1st 0 2nd KEGG 6 hsa05310:Asthma 
1st 0 2nd KEGG 6 hsa05320:Autoimmune thyroid disease 
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1st 0 2nd KEGG 6 hsa05322:Systemic lupus erythematosus 
1st 0 2nd KEGG 6 hsa05330:Allograft rejection 
1st 0 2nd KEGG 6 hsa05332:Graft-versus-host disease 
1st 0 2nd KEGG 6 hsa05416:Viral myocarditis 
1st 0 2nd KEGG 7 hsa00510:N-Glycan biosynthesis 
1st 0 2nd KEGG 7 hsa00512:O-Glycan biosynthesis 
1st 0 2nd KEGG 7 hsa00531:Glycosaminoglycan degradation 
1st 0 2nd KEGG 7 hsa00533:Keratan sulfate biosynthesis 
1st 0 2nd KEGG 7 hsa00562:Inositol phosphate metabolism 
1st 0 2nd KEGG 7 hsa00770:Pantothenate and CoA biosynthesis 
1st 0 2nd KEGG 7 hsa03040:Spliceosome 
1st 0 2nd KEGG 7 hsa03060:Protein export 
1st 0 2nd KEGG 7 hsa04010:MAPK signaling pathway 
1st 0 2nd KEGG 7 hsa04060:Cytokine-cytokine receptor interaction 
1st 0 2nd KEGG 7 hsa04062:Chemokine signaling pathway 
1st 0 2nd KEGG 7 hsa04070:Phosphatidylinositol signaling system 
1st 0 2nd KEGG 7 hsa04080:Neuroactive ligand-receptor interaction 
1st 0 2nd KEGG 7 hsa04110:Cell cycle 
1st 0 2nd KEGG 7 hsa04142:Lysosome 
1st 0 2nd KEGG 7 hsa04144:Endocytosis 
1st 0 2nd KEGG 7 hsa04310:Wnt signaling pathway 
1st 0 2nd KEGG 7 hsa04320:Dorso-ventral axis formation 
1st 0 2nd KEGG 7 hsa04350:TGF-beta signaling pathway 
1st 0 2nd KEGG 7 hsa04360:Axon guidance 
1st 0 2nd KEGG 7 hsa04530:Tight junction 
1st 0 2nd KEGG 7 hsa04630:Jak-STAT signaling pathway 
1st 0 2nd KEGG 7 hsa04666:Fc gamma R-mediated phagocytosis 
1st 0 2nd KEGG 7 
hsa04672:Intestinal immune network for IgA 
production 
1st 0 2nd KEGG 7 hsa04740:Olfactory transduction 
1st 0 2nd KEGG 7 hsa04910:Insulin signaling pathway 
1st 0 2nd KEGG 7 hsa04920:Adipocytokine signaling pathway 
1st 0 2nd KEGG 7 hsa04930:Type II diabetes mellitus 
1st 0 2nd KEGG 7 hsa05200:Pathways in cancer 
1st 0 2nd KEGG 7 hsa05210:Colorectal cancer 
1st 0 2nd KEGG 7 hsa05211:Renal cell carcinoma 
1st 0 2nd KEGG 7 hsa05212:Pancreatic cancer 
1st 0 2nd KEGG 7 hsa05215:Prostate cancer 
1st 0 2nd KEGG 7 hsa05220:Chronic myeloid leukemia 
1st 0 2nd KEGG 7 hsa05410:Hypertrophic cardiomyopathy (HCM) 
1st 0 2nd KEGG 7 hsa05414:Dilated cardiomyopathy 
1st 0 2nd KEGG 8 hsa04144:Endocytosis 
1st 0 2nd KEGG 8 hsa04514:Cell adhesion molecules (CAMs) 
1st 0 2nd KEGG 8 hsa04612:Antigen processing and presentation 
1st 0 2nd KEGG 8 hsa04650:Natural killer cell mediated cytotoxicity 
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1st 0 2nd KEGG 8 
hsa04672:Intestinal immune network for IgA 
production 
1st 0 2nd KEGG 8 hsa04740:Olfactory transduction 
1st 0 2nd KEGG 8 hsa04940:Type I diabetes mellitus 
1st 0 2nd KEGG 8 hsa05016:Huntington's disease 
1st 0 2nd KEGG 8 hsa05310:Asthma 
1st 0 2nd KEGG 8 hsa05320:Autoimmune thyroid disease 
1st 0 2nd KEGG 8 hsa05322:Systemic lupus erythematosus 
1st 0 2nd KEGG 8 hsa05330:Allograft rejection 
1st 0 2nd KEGG 8 hsa05332:Graft-versus-host disease 
1st 0 2nd KEGG 8 hsa05416:Viral myocarditis 
1st 0 2nd KEGG 9 hsa04514:Cell adhesion molecules (CAMs) 
1st 0 2nd KEGG 9 hsa04612:Antigen processing and presentation 
1st 0 2nd KEGG 9 
hsa04672:Intestinal immune network for IgA 
production 
1st 0 2nd KEGG 9 hsa04940:Type I diabetes mellitus 
1st 0 2nd KEGG 9 hsa05310:Asthma 
1st 0 2nd KEGG 9 hsa05320:Autoimmune thyroid disease 
1st 0 2nd KEGG 9 hsa05322:Systemic lupus erythematosus 
1st 0 2nd KEGG 9 hsa05330:Allograft rejection 
1st 0 2nd KEGG 9 hsa05332:Graft-versus-host disease 
1st 0 2nd KEGG 9 hsa05416:Viral myocarditis 
1st 0 2nd KEGG 10 hsa00512:O-Glycan biosynthesis 
1st 0 2nd KEGG 10 hsa04510:Focal adhesion 
1st 0 2nd KEGG 10 hsa04514:Cell adhesion molecules (CAMs) 
1st 0 2nd KEGG 10 hsa04612:Antigen processing and presentation 
1st 0 2nd KEGG 10 
hsa04672:Intestinal immune network for IgA 
production 
1st 0 2nd KEGG 10 hsa04810:Regulation of actin cytoskeleton 
1st 0 2nd KEGG 10 hsa04940:Type I diabetes mellitus 
1st 0 2nd KEGG 10 hsa05310:Asthma 
1st 0 2nd KEGG 10 hsa05320:Autoimmune thyroid disease 
1st 0 2nd KEGG 10 hsa05322:Systemic lupus erythematosus 
1st 0 2nd KEGG 10 hsa05330:Allograft rejection 
1st 0 2nd KEGG 10 hsa05332:Graft-versus-host disease 
1st 0 2nd KEGG 10 hsa05416:Viral myocarditis 
2nd 0 2nd KEGG 1 hsa04740:Olfactory transduction 
2nd 0 2nd KEGG 4 hsa04340:Hedgehog signaling pathway 
2nd 0 2nd KEGG 4 hsa04740:Olfactory transduction 
2nd 0 2nd KEGG 6 hsa04514:Cell adhesion molecules (CAMs) 
2nd 0 2nd KEGG 6 hsa04612:Antigen processing and presentation 
2nd 0 2nd KEGG 6 hsa04640:Hematopoietic cell lineage 
2nd 0 2nd KEGG 6 
hsa04672:Intestinal immune network for IgA 
production 
2nd 0 2nd KEGG 6 hsa04940:Type I diabetes mellitus 
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2nd 0 2nd KEGG 6 hsa05310:Asthma 
2nd 0 2nd KEGG 6 hsa05320:Autoimmune thyroid disease 
2nd 0 2nd KEGG 6 hsa05322:Systemic lupus erythematosus 
2nd 0 2nd KEGG 6 hsa05330:Allograft rejection 
2nd 0 2nd KEGG 6 hsa05332:Graft-versus-host disease 
2nd 0 2nd KEGG 6 hsa05416:Viral myocarditis 
2nd 0 2nd KEGG 7 hsa00510:N-Glycan biosynthesis 
2nd 0 2nd KEGG 7 hsa00531:Glycosaminoglycan degradation 
2nd 0 2nd KEGG 7 hsa00533:Keratan sulfate biosynthesis 
2nd 0 2nd KEGG 7 hsa00562:Inositol phosphate metabolism 
2nd 0 2nd KEGG 7 hsa00770:Pantothenate and CoA biosynthesis 
2nd 0 2nd KEGG 7 hsa03060:Protein export 
2nd 0 2nd KEGG 7 hsa04010:MAPK signaling pathway 
2nd 0 2nd KEGG 7 hsa04060:Cytokine-cytokine receptor interaction 
2nd 0 2nd KEGG 7 hsa04062:Chemokine signaling pathway 
2nd 0 2nd KEGG 7 hsa04070:Phosphatidylinositol signaling system 
2nd 0 2nd KEGG 7 hsa04080:Neuroactive ligand-receptor interaction 
2nd 0 2nd KEGG 7 hsa04110:Cell cycle 
2nd 0 2nd KEGG 7 hsa04142:Lysosome 
2nd 0 2nd KEGG 7 hsa04144:Endocytosis 
2nd 0 2nd KEGG 7 hsa04310:Wnt signaling pathway 
2nd 0 2nd KEGG 7 hsa04320:Dorso-ventral axis formation 
2nd 0 2nd KEGG 7 hsa04350:TGF-beta signaling pathway 
2nd 0 2nd KEGG 7 hsa04360:Axon guidance 
2nd 0 2nd KEGG 7 hsa04530:Tight junction 
2nd 0 2nd KEGG 7 hsa04630:Jak-STAT signaling pathway 
2nd 0 2nd KEGG 7 hsa04666:Fc gamma R-mediated phagocytosis 
2nd 0 2nd KEGG 7 
hsa04672:Intestinal immune network for IgA 
production 
2nd 0 2nd KEGG 7 hsa04740:Olfactory transduction 
2nd 0 2nd KEGG 7 hsa04910:Insulin signaling pathway 
2nd 0 2nd KEGG 7 hsa04920:Adipocytokine signaling pathway 
2nd 0 2nd KEGG 7 hsa04930:Type II diabetes mellitus 
2nd 0 2nd KEGG 7 hsa05200:Pathways in cancer 
2nd 0 2nd KEGG 7 hsa05210:Colorectal cancer 
2nd 0 2nd KEGG 7 hsa05211:Renal cell carcinoma 
2nd 0 2nd KEGG 7 hsa05212:Pancreatic cancer 
2nd 0 2nd KEGG 7 hsa05215:Prostate cancer 
2nd 0 2nd KEGG 7 hsa05220:Chronic myeloid leukemia 
2nd 0 2nd KEGG 7 hsa05410:Hypertrophic cardiomyopathy (HCM) 
2nd 0 2nd KEGG 7 hsa05414:Dilated cardiomyopathy 
1st 1 2nd KEGG 1 hsa04740:Olfactory transduction 
1st 1 2nd KEGG 4 hsa04740:Olfactory transduction 
1st 1 2nd KEGG 7 hsa00533:Keratan sulfate biosynthesis 
1st 1 2nd KEGG 7 hsa04740:Olfactory transduction 
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1st 1 2nd KEGG 8 hsa04740:Olfactory transduction 
2nd 1 2nd KEGG 1 hsa04740:Olfactory transduction 
2nd 1 2nd KEGG 4 hsa04740:Olfactory transduction 
2nd 1 2nd KEGG 7 hsa00533:Keratan sulfate biosynthesis 
1st 0 1st Panther 1 P00010:B cell activation 
1st 0 1st Panther 1 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
1st 0 1st Panther 1 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 1st Panther 1 
P00028:Heterotrimeric G-protein signaling pathway-
rod outer segment phototransduction 
1st 0 1st Panther 1 
P00043:Muscarinic acetylcholine receptor 2 and 4 
signaling pathway 
1st 0 1st Panther 1 P00049:Parkinson disease 
1st 0 1st Panther 2 P00012:Cadherin signaling pathway 
1st 0 1st Panther 2 P00034:Integrin signalling pathway 
1st 0 1st Panther 2 P00057:Wnt signaling pathway 
1st 0 1st Panther 3 P00047:PDGF signaling pathway 
1st 0 1st Panther 3 P00049:Parkinson disease 
1st 0 1st Panther 5 P00007:Axon guidance mediated by semaphorins 
1st 0 1st Panther 5 P00029:Huntington disease 
1st 0 1st Panther 5 P00034:Integrin signalling pathway 
1st 0 1st Panther 6 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
1st 0 1st Panther 6 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 1st Panther 7 P00002:Alpha adrenergic receptor signaling pathway 
1st 0 1st Panther 7 
P00003:Alzheimer disease-amyloid secretase 
pathway 
1st 0 1st Panther 7 P00004:Alzheimer disease-presenilin pathway 
1st 0 1st Panther 7 P00005:Angiogenesis 
1st 0 1st Panther 7 P00006:Apoptosis signaling pathway 
1st 0 1st Panther 7 P00010:B cell activation 
1st 0 1st Panther 7 P00012:Cadherin signaling pathway 
1st 0 1st Panther 7 P00018:EGF receptor signaling pathway 
1st 0 1st Panther 7 P00019:Endothelin signaling pathway 
1st 0 1st Panther 7 P00021:FGF signaling pathway 
1st 0 1st Panther 7 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
1st 0 1st Panther 7 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 1st Panther 7 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
1st 0 1st Panther 7 
P00041:Metabotropic glutamate receptor group I 
pathway 
1st 0 1st Panther 7 
P00042:Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
  
97 
1st 0 1st Panther 7 P00045:Notch signaling pathway 
1st 0 1st Panther 7 P00047:PDGF signaling pathway 
1st 0 1st Panther 7 P00053:T cell activation 
1st 0 1st Panther 7 P00056:VEGF signaling pathway 
1st 0 1st Panther 7 P00057:Wnt signaling pathway 
1st 0 1st Panther 7 
P04374:5HT2 type receptor mediated signaling 
pathway 
1st 0 1st Panther 7 
P04385:Histamine H1 receptor mediated signaling 
pathway 
1st 0 1st Panther 7 
P04391:Oxytocin receptor mediated signaling 
pathway 
1st 0 1st Panther 7 
P04394:Thyrotropin-releasing hormone receptor 
signaling pathway 
1st 0 1st Panther 7 
P05911:Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin 
1st 0 1st Panther 7 
P05912:Dopamine receptor mediated signaling 
pathway 
1st 0 1st Panther 8 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
1st 0 1st Panther 9 P00002:Alpha adrenergic receptor signaling pathway 
1st 0 1st Panther 9 
P00003:Alzheimer disease-amyloid secretase 
pathway 
1st 0 1st Panther 9 P00005:Angiogenesis 
1st 0 1st Panther 9 P00006:Apoptosis signaling pathway 
1st 0 1st Panther 9 P00010:B cell activation 
1st 0 1st Panther 9 P00012:Cadherin signaling pathway 
1st 0 1st Panther 9 P00018:EGF receptor signaling pathway 
1st 0 1st Panther 9 P00019:Endothelin signaling pathway 
1st 0 1st Panther 9 P00021:FGF signaling pathway 
1st 0 1st Panther 9 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 1st Panther 9 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
1st 0 1st Panther 9 P00037:Ionotropic glutamate receptor pathway 
1st 0 1st Panther 9 
P00039:Metabotropic glutamate receptor group III 
pathway 
1st 0 1st Panther 9 
P00041:Metabotropic glutamate receptor group I 
pathway 
1st 0 1st Panther 9 
P00042:Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
1st 0 1st Panther 9 P00047:PDGF signaling pathway 
1st 0 1st Panther 9 P00056:VEGF signaling pathway 
1st 0 1st Panther 9 P00057:Wnt signaling pathway 
1st 0 1st Panther 9 
P04374:5HT2 type receptor mediated signaling 
pathway 
1st 0 1st Panther 9 
P04385:Histamine H1 receptor mediated signaling 
pathway 
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1st 0 1st Panther 9 P00053:T cell activation 
1st 0 1st Panther 9 
P04394:Thyrotropin-releasing hormone receptor 
signaling pathway 
1st 0 1st Panther 9 
P05911:Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin 
1st 0 1st Panther 10 P00015:Circadian clock system 
1st 0 1st Panther 10 P00025:Hedgehog signaling pathway 
1st 0 1st Panther 10 P00029:Huntington disease 
1st 0 1st Panther 10 P00049:Parkinson disease 
1st 0 1st Panther 10 P00057:Wnt signaling pathway 
2nd 0 1st Panther 2 P00012:Cadherin signaling pathway 
2nd 0 1st Panther 2 P00057:Wnt signaling pathway 
2nd 0 1st Panther 5 P00029:Huntington disease 
2nd 0 1st Panther 7 
P00003:Alzheimer disease-amyloid secretase 
pathway 
2nd 0 1st Panther 7 P00004:Alzheimer disease-presenilin pathway 
2nd 0 1st Panther 7 P00005:Angiogenesis 
2nd 0 1st Panther 7 P00012:Cadherin signaling pathway 
2nd 0 1st Panther 7 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
2nd 0 1st Panther 7 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
2nd 0 1st Panther 7 P00057:Wnt signaling pathway 
2nd 0 1st Panther 7 
P05912:Dopamine receptor mediated signaling 
pathway 
2nd 0 1st Panther 10 P00015:Circadian clock system 
2nd 0 1st Panther 10 P00025:Hedgehog signaling pathway 
2nd 0 1st Panther 10 P00049:Parkinson disease 
2nd 0 1st Panther 10 P00057:Wnt signaling pathway 
1st 1 1st Panther 6 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
1st 1 1st Panther 6 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 1 1st Panther 7 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
1st 1 1st Panther 7 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 1 1st Panther 7 P00045:Notch signaling pathway 
1st 1 1st Panther 7 P00057:Wnt signaling pathway 
1st 1 1st Panther 7 
P05912:Dopamine receptor mediated signaling 
pathway 
1st 1 1st Panther 9 P00037:Ionotropic glutamate receptor pathway 
1st 1 1st Panther 9 
P00039:Metabotropic glutamate receptor group III 
pathway 
1st 1 1st Panther 9 P00047:PDGF signaling pathway 
2nd 1 1st Panther 7 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
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2nd 1 1st Panther 7 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
2nd 1 1st Panther 7 P00057:Wnt signaling pathway 
2nd 1 1st Panther 7 
P05912:Dopamine receptor mediated signaling 
pathway 
1st 0 2nd Panther 3 P00002:Alpha adrenergic receptor signaling pathway 
1st 0 2nd Panther 3 
P00003:Alzheimer disease-amyloid secretase 
pathway 
1st 0 2nd Panther 3 P00005:Angiogenesis 
1st 0 2nd Panther 3 P00006:Apoptosis signaling pathway 
1st 0 2nd Panther 3 P00010:B cell activation 
1st 0 2nd Panther 3 P00018:EGF receptor signaling pathway 
1st 0 2nd Panther 3 P00019:Endothelin signaling pathway 
1st 0 2nd Panther 3 P00021:FGF signaling pathway 
1st 0 2nd Panther 3 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 2nd Panther 3 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
1st 0 2nd Panther 3 
P00041:Metabotropic glutamate receptor group I 
pathway 
1st 0 2nd Panther 3 
P00042:Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
1st 0 2nd Panther 3 P00047:PDGF signaling pathway 
1st 0 2nd Panther 3 P00053:T cell activation 
1st 0 2nd Panther 3 P00056:VEGF signaling pathway 
1st 0 2nd Panther 3 P00057:Wnt signaling pathway 
1st 0 2nd Panther 3 
P04374:5HT2 type receptor mediated signaling 
pathway 
1st 0 2nd Panther 3 
P04385:Histamine H1 receptor mediated signaling 
pathway 
1st 0 2nd Panther 3 
P04391:Oxytocin receptor mediated signaling 
pathway 
1st 0 2nd Panther 3 
P04394:Thyrotropin-releasing hormone receptor 
signaling pathway 
1st 0 2nd Panther 3 
P05911:Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin 
1st 0 2nd Panther 4 P00015:Circadian clock system 
1st 0 2nd Panther 4 P00025:Hedgehog signaling pathway 
1st 0 2nd Panther 4 P00049:Parkinson disease 
1st 0 2nd Panther 4 P00057:Wnt signaling pathway 
1st 0 2nd Panther 6 P00002:Alpha adrenergic receptor signaling pathway 
1st 0 2nd Panther 6 
P00003:Alzheimer disease-amyloid secretase 
pathway 
1st 0 2nd Panther 6 P00005:Angiogenesis 
1st 0 2nd Panther 6 P00006:Apoptosis signaling pathway 
1st 0 2nd Panther 6 P00010:B cell activation 
1st 0 2nd Panther 6 P00018:EGF receptor signaling pathway 
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1st 0 2nd Panther 6 P00019:Endothelin signaling pathway 
1st 0 2nd Panther 6 P00021:FGF signaling pathway 
1st 0 2nd Panther 6 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 2nd Panther 6 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
1st 0 2nd Panther 6 
P00041:Metabotropic glutamate receptor group I 
pathway 
1st 0 2nd Panther 6 
P00042:Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
1st 0 2nd Panther 6 P00047:PDGF signaling pathway 
1st 0 2nd Panther 6 P00053:T cell activation 
1st 0 2nd Panther 6 P00056:VEGF signaling pathway 
1st 0 2nd Panther 6 P00057:Wnt signaling pathway 
1st 0 2nd Panther 6 
P04374:5HT2 type receptor mediated signaling 
pathway 
1st 0 2nd Panther 6 
P04385:Histamine H1 receptor mediated signaling 
pathway 
1st 0 2nd Panther 6 
P04391:Oxytocin receptor mediated signaling 
pathway 
1st 0 2nd Panther 6 
P04394:Thyrotropin-releasing hormone receptor 
signaling pathway 
1st 0 2nd Panther 6 
P05911:Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin 
1st 0 2nd Panther 7 P00002:Alpha adrenergic receptor signaling pathway 
1st 0 2nd Panther 7 
P00003:Alzheimer disease-amyloid secretase 
pathway 
1st 0 2nd Panther 7 P00005:Angiogenesis 
1st 0 2nd Panther 7 P00006:Apoptosis signaling pathway 
1st 0 2nd Panther 7 P00007:Axon guidance mediated by semaphorins 
1st 0 2nd Panther 7 P00010:B cell activation 
1st 0 2nd Panther 7 P00018:EGF receptor signaling pathway 
1st 0 2nd Panther 7 P00019:Endothelin signaling pathway 
1st 0 2nd Panther 7 P00021:FGF signaling pathway 
1st 0 2nd Panther 7 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
1st 0 2nd Panther 7 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
1st 0 2nd Panther 7 
P00028:Heterotrimeric G-protein signaling pathway-
rod outer segment phototransduction 
1st 0 2nd Panther 7 P00029:Huntington disease 
1st 0 2nd Panther 7 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
1st 0 2nd Panther 7 
P00033:Insulin/IGF pathway-protein kinase B 
signaling cascade 
1st 0 2nd Panther 7 P00035:Interferon-gamma signaling pathway 
1st 0 2nd Panther 7 P00036:Interleukin signaling pathway 
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1st 0 2nd Panther 7 P00037:Ionotropic glutamate receptor pathway 
1st 0 2nd Panther 7 P00038:JAK/STAT signaling pathway 
1st 0 2nd Panther 7 
P00039:Metabotropic glutamate receptor group III 
pathway 
1st 0 2nd Panther 7 
P00041:Metabotropic glutamate receptor group I 
pathway 
1st 0 2nd Panther 7 
P00042:Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
1st 0 2nd Panther 7 
P00044:Nicotinic acetylcholine receptor signaling 
pathway 
1st 0 2nd Panther 7 P00047:PDGF signaling pathway 
1st 0 2nd Panther 7 P00048:PI3 kinase pathway 
1st 0 2nd Panther 7 P00052:TGF-beta signaling pathway 
1st 0 2nd Panther 7 P00053:T cell activation 
1st 0 2nd Panther 7 P00056:VEGF signaling pathway 
1st 0 2nd Panther 7 P00057:Wnt signaling pathway 
1st 0 2nd Panther 7 P02736:Coenzyme A biosynthesis 
1st 0 2nd Panther 7 
P04374:5HT2 type receptor mediated signaling 
pathway 
1st 0 2nd Panther 7 
P04385:Histamine H1 receptor mediated signaling 
pathway 
1st 0 2nd Panther 7 
P04391:Oxytocin receptor mediated signaling 
pathway 
1st 0 2nd Panther 7 
P04394:Thyrotropin-releasing hormone receptor 
signaling pathway 
1st 0 2nd Panther 7 
P05911:Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin 
1st 0 2nd Panther 7 P05913:Enkephalin release 
1st 0 2nd Panther 7 P05915:Opioid proenkephalin pathway 
1st 0 2nd Panther 7 P05917:Opioid proopiomelanocortin pathway 
1st 0 2nd Panther 8 P00029:Huntington disease 
1st 0 2nd Panther 8 P00053:T cell activation 
1st 0 2nd Panther 9 P00053:T cell activation 
1st 0 2nd Panther 10 P00034:Integrin signalling pathway 
1st 0 2nd Panther 10 P00053:T cell activation 
2nd 0 2nd Panther 4 P00015:Circadian clock system 
2nd 0 2nd Panther 4 P00025:Hedgehog signaling pathway 
2nd 0 2nd Panther 4 P00049:Parkinson disease 
2nd 0 2nd Panther 4 P00057:Wnt signaling pathway 
2nd 0 2nd Panther 7 P00002:Alpha adrenergic receptor signaling pathway 
2nd 0 2nd Panther 7 
P00003:Alzheimer disease-amyloid secretase 
pathway 
2nd 0 2nd Panther 7 P00005:Angiogenesis 
2nd 0 2nd Panther 7 P00006:Apoptosis signaling pathway 
2nd 0 2nd Panther 7 P00007:Axon guidance mediated by semaphorins 
2nd 0 2nd Panther 7 P00010:B cell activation 
2nd 0 2nd Panther 7 P00018:EGF receptor signaling pathway 
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2nd 0 2nd Panther 7 P00019:Endothelin signaling pathway 
2nd 0 2nd Panther 7 P00021:FGF signaling pathway 
2nd 0 2nd Panther 7 
P00026:Heterotrimeric G-protein signaling pathway-
Gi alpha and Gs alpha mediated pathway 
2nd 0 2nd Panther 7 
P00027:Heterotrimeric G-protein signaling pathway-
Gq alpha and Go alpha mediated pathway 
2nd 0 2nd Panther 7 
P00028:Heterotrimeric G-protein signaling pathway-
rod outer segment phototransduction 
2nd 0 2nd Panther 7 P00029:Huntington disease 
2nd 0 2nd Panther 7 
P00031:Inflammation mediated by chemokine and 
cytokine signaling pathway 
2nd 0 2nd Panther 7 
P00033:Insulin/IGF pathway-protein kinase B 
signaling cascade 
2nd 0 2nd Panther 7 P00035:Interferon-gamma signaling pathway 
2nd 0 2nd Panther 7 P00036:Interleukin signaling pathway 
2nd 0 2nd Panther 7 P00037:Ionotropic glutamate receptor pathway 
2nd 0 2nd Panther 7 P00038:JAK/STAT signaling pathway 
2nd 0 2nd Panther 7 
P00039:Metabotropic glutamate receptor group III 
pathway 
2nd 0 2nd Panther 7 
P00041:Metabotropic glutamate receptor group I 
pathway 
2nd 0 2nd Panther 7 
P00042:Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
2nd 0 2nd Panther 7 P00047:PDGF signaling pathway 
2nd 0 2nd Panther 7 P00048:PI3 kinase pathway 
2nd 0 2nd Panther 7 P00052:TGF-beta signaling pathway 
2nd 0 2nd Panther 7 P00053:T cell activation 
2nd 0 2nd Panther 7 P00056:VEGF signaling pathway 
2nd 0 2nd Panther 7 P00057:Wnt signaling pathway 
2nd 0 2nd Panther 7 P02736:Coenzyme A biosynthesis 
2nd 0 2nd Panther 7 
P04374:5HT2 type receptor mediated signaling 
pathway 
2nd 0 2nd Panther 7 
P04385:Histamine H1 receptor mediated signaling 
pathway 
2nd 0 2nd Panther 7 
P04391:Oxytocin receptor mediated signaling 
pathway 
2nd 0 2nd Panther 7 
P04394:Thyrotropin-releasing hormone receptor 
signaling pathway 
2nd 0 2nd Panther 7 
P05911:Angiotensin II-stimulated signaling through 
G proteins and beta-arrestin 
1st 0 1st Reactome 2 REACT_6900:Signaling in Immune system, 
1st 0 1st Reactome 3 REACT_11045:Signaling by Wnt 
1st 0 1st Reactome 3 REACT_13:Metabolism of amino acids 
1st 0 1st Reactome 3 
REACT_13635:Regulation of activated PAK-2p34 
by proteasome mediated degradation 
1st 0 1st Reactome 3 REACT_152:Cell Cycle, Mitotic 
1st 0 1st Reactome 3 REACT_1538:Cell Cycle Checkpoints 
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1st 0 1st Reactome 3 REACT_383:DNA Replication 
1st 0 1st Reactome 3 REACT_578:Apoptosis 
1st 0 1st Reactome 3 REACT_6185:HIV Infection 
1st 0 1st Reactome 3 
REACT_6850:Cdc20:Phospho-APC/C mediated 
degradation of Cyclin A 
1st 0 1st Reactome 3 REACT_6900:Signaling in Immune system 
1st 0 1st Reactome 3 
REACT_9035:APC/C:Cdh1-mediated degradation of 
Skp2 
1st 0 1st Reactome 3 
REACT_9480:Gap junction trafficking and 
regulation 
1st 0 1st Reactome 5 REACT_71:Gene Expression 
1st 0 1st Reactome 6 REACT_14797:Signaling by GPCR 
1st 0 1st Reactome 6 REACT_6900:Signaling in Immune system 
1st 0 1st Reactome 7 REACT_14797:Signaling by GPCR 
1st 0 1st Reactome 7 REACT_6900:Signaling in Immune system 
1st 0 1st Reactome 8 
REACT_15518:Transmembrane transport of small 
molecules 
1st 0 1st Reactome 9 REACT_13685:Synaptic Transmission 
1st 0 1st Reactome 9 REACT_15380:Diabetes pathways 
1st 0 1st Reactome 9 REACT_604:Hemostasis 
1st 0 1st Reactome 9 REACT_71:Gene Expression 
1st 0 1st Reactome 10 REACT_14797:Signaling by GPCR 
2nd 0 1st Reactome 2 REACT_6900:Signaling in Immune system 
2nd 0 1st Reactome 3 REACT_6900:Signaling in Immune system 
2nd 0 1st Reactome 6 REACT_6900:Signaling in Immune system 
2nd 0 1st Reactome 7 REACT_14797:Signaling by GPCR 
2nd 0 1st Reactome 10 REACT_14797:Signaling by GPCR 
1st 1 1st Reactome 5 REACT_71:Gene Expression,   
1st 1 1st Reactome 6 REACT_14797:Signaling by GPCR 
1st 1 1st Reactome 7 REACT_14797:Signaling by GPCR 
1st 1 1st Reactome 7 REACT_6900:Signaling in Immune system 
1st 1 1st Reactome 8 
REACT_15518:Transmembrane transport of small 
molecules 
1st 1 1st Reactome 9 REACT_13685:Synaptic Transmission 
1st 1 1st Reactome 9 REACT_71:Gene Expression 
1st 1 1st Reactome 10 REACT_14797:Signaling by GPCR 
2nd 1 1st Reactome 7 REACT_14797:Signaling by GPCR 
2nd 1 1st Reactome 10 REACT_14797:Signaling by GPCR 
1st 0 2nd Reactome 1 REACT_14797:Signaling by GPCR 
1st 0 2nd Reactome 2 REACT_17015:Metabolism of proteins 
1st 0 2nd Reactome 3 REACT_13685:Synaptic Transmission 
1st 0 2nd Reactome 3 REACT_15380:Diabetes pathways 
1st 0 2nd Reactome 3 REACT_604:Hemostasis 
1st 0 2nd Reactome 3 REACT_6900:Signaling in Immune system 
1st 0 2nd Reactome 4 REACT_14797:Signaling by GPCR 
1st 0 2nd Reactome 6 REACT_13685:Synaptic Transmission 
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1st 0 2nd Reactome 6 REACT_15380:Diabetes pathways 
1st 0 2nd Reactome 6 REACT_604:Hemostasis 
1st 0 2nd Reactome 6 REACT_6900:Signaling in Immune system 
1st 0 2nd Reactome 7 REACT_11061:Signalling by NGF 
1st 0 2nd Reactome 7 
REACT_11193:Metabolism of vitamins and 
cofactors 
1st 0 2nd Reactome 7 REACT_13:Metabolism of amino acids 
1st 0 2nd Reactome 7 REACT_13698:Regulation of beta-cell development 
1st 0 2nd Reactome 7 REACT_14797:Signaling by GPCR 
1st 0 2nd Reactome 7 REACT_15295:Opioid Signalling 
1st 0 2nd Reactome 7 REACT_15380:Diabetes pathways 
1st 0 2nd Reactome 7 
REACT_15518:Transmembrane transport of small 
molecules 
1st 0 2nd Reactome 7 REACT_17015:Metabolism of proteins 
1st 0 2nd Reactome 7 
REACT_1762:3' -UTR-mediated translational 
regulation 
1st 0 2nd Reactome 7 REACT_18266:Axon guidance 
1st 0 2nd Reactome 7 REACT_216:DNA Repair 
1st 0 2nd Reactome 7 REACT_604:Hemostasis 
1st 0 2nd Reactome 7 REACT_6167:Influenza Infection 
1st 0 2nd Reactome 7 REACT_6844:Signaling by TGF beta 
1st 0 2nd Reactome 7 REACT_71:Gene Expression 
1st 0 2nd Reactome 8 REACT_6900:Signaling in Immune system 
1st 0 2nd Reactome 9 REACT_6900:Signaling in Immune system 
1st 0 2nd Reactome 10 REACT_6900:Signaling in Immune system 
2nd 0 2nd Reactome 1 REACT_14797:Signaling by GPCR 
2nd 0 2nd Reactome 4 REACT_14797:Signaling by GPCR 
2nd 0 2nd Reactome 6 REACT_6900:Signaling in Immune system 
2nd 0 2nd Reactome 7 REACT_11061:Signalling by NGF 
2nd 0 2nd Reactome 7 
REACT_11193:Metabolism of vitamins and 
cofactors 
2nd 0 2nd Reactome 7 REACT_13:Metabolism of amino acids 
2nd 0 2nd Reactome 7 REACT_13698:Regulation of beta-cell development 
2nd 0 2nd Reactome 7 REACT_14797:Signaling by GPCR 
2nd 0 2nd Reactome 7 REACT_15380:Diabetes pathways 
2nd 0 2nd Reactome 7 
REACT_15518:Transmembrane transport of small 
molecules 
2nd 0 2nd Reactome 7 REACT_17015:Metabolism of proteins 
2nd 0 2nd Reactome 7 
REACT_1762:3' -UTR-mediated translational 
regulation 
2nd 0 2nd Reactome 7 REACT_216:DNA Repair 
2nd 0 2nd Reactome 7 REACT_604:Hemostasis 
2nd 0 2nd Reactome 7 REACT_6167:Influenza Infection 
2nd 0 2nd Reactome 7 REACT_6844:Signaling by TGF beta 
2nd 0 2nd Reactome 7 REACT_71:Gene Expression 
1st 1 2nd Reactome 1 REACT_14797:Signaling by GPCR 
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1st 1 2nd Reactome 4 REACT_14797:Signaling by GPCR 
1st 1 2nd Reactome 7 REACT_13:Metabolism of amino acids 
1st 1 2nd Reactome 7 REACT_14797:Signaling by GPCR 
1st 1 2nd Reactome 7 
REACT_15518:Transmembrane transport of small 
molecules 
2nd 1 2nd Reactome 1 REACT_14797:Signaling by GPCR 
2nd 1 2nd Reactome 4 REACT_14797:Signaling by GPCR 
2nd 1 2nd Reactome 7 REACT_13:Metabolism of amino acids 
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APPENDIX C  
 
Family Results for the Analysis with Normalization 
 
 List of most significant pathways for each family are presented in this section. 
Pathways are ranked according to p-values and most significant 10 pathways are 
included for each family. If there are less than 10 pathways, all pathways are presented 
for that family. If the analysis did not yield any results for a family, a table is not 
provided.  
 
 All results in this section are obtained by third approach analysis with 
normalization using second filter.  
 
 
KEGG Pathway P-values 
Allograft rejection 1,98E+08 
Table C.1 General analysis results for family trio 3 
  
KEGG Pathway P-values 
Circadian rhythm 7,20E+03 
Amphetamine addiction 3,05E+05 
Proteasome 5,86E+07 
Table C.2 General analysis results for family trio 4 
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KEGG Pathway P-values 
Asthma 5,60E+01 
Allograft rejection 2,01E+04 
Graft-versus-host disease 2,78E+04 
Type I diabetes mellitus 3,76E+02 
Intestinal immune network for IgA production 9,80E+03 
Autoimmune thyroid disease 1,59E+04 
Staphylococcus aureus infection 2,23E+04 
Table C.3 General analysis results for family trio 6 
 
KEGG Pathway P-values 
Complement and coagulation cascades 4,80E-14 
TGF-beta signaling pathway 7,41E-06 
GABAergic synapse 2,52E+04 
Proteasome 5,92E+04 
RNA degradation 8,40E+04 
Notch signaling pathway 3,90E+06 
Type II diabetes mellitus 2,69E+06 
Aldosterone-regulated sodium reabsorption 7,50E+05 
Pentose phosphate pathway 1,37E+09 
Homologous recombination 3,22E+07 
Table C.4 General analysis results for family trio 7 
 
KEGG Pathway P-values 
Complement and coagulation cascades 4,80E-14 
TGF-beta signaling pathway 7,41E-06 
GABAergic synapse 2,52E+04 
Proteasome 5,92E+04 
RNA degradation 8,40E+04 
Notch signaling pathway 3,90E+06 
Circadian rhythm 1,77E+07 
Type II diabetes mellitus 2,69E+06 
Aldosterone-regulated sodium reabsorption 7,50E+05 
Pentose phosphate pathway 1,37E+09 
Table C.5 General analysis results for family trio 8 
 
KEGG Pathway P-values 
Folate biosynthesis 2,83E+11 
Table C.6 General analysis results for family trio 9 
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KEGG Pathway P-values 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 1,15E+10 
Renin-angiotensin system 4,23E+11 
Table C.7 Promoter analysis results for family trio 6 
 
KEGG Pathway P-values 
DNA replication 6,19E-11 
Complement and coagulation cascades 9,95E-05 
Cholinergic synapse 4,31E-03 
Glutamatergic synapse 3,49E-02 
GABAergic synapse 1,45E+00 
Retrograde endocannabinoid signaling 7,79E-01 
Dopaminergic synapse 1,88E+01 
Notch signaling pathway 1,22E+03 
Proteasome 7,16E+03 
ECM-receptor interaction 7,44E+03 
Table C.8Promoter analysis results for family trio 7 
 
KEGG Pathway P-values 
Folate biosynthesis 1,42E+11 
Table C.9 Promoter analysis results for family trio 9 
  
 
